ARYAVAIDYAN A QUARTERLY JOURNAL ON AYURVEDA AND ALLIED SCIENCES

ISSN 0970 - 4086

Vol. XXXII, No. 3

February - April 2019



लाभानां श्रेय आरोग्यम्

Of all the gifts, the most precious is health



Vaidyaratnam P.S. Varier's Arya Vaidya Sala, Kottakkal, Kerala

Aryavaidyan, the quarterly journal of Arya Vaidya Sala, Kottakkal, is intended to encourage scientific writing and intellectual interactions among scholars, academicians, practitioners and students of ayurveda and allied

Patron **Dr. P.K. Warrier**

Advisory Board

Ashtavaidyan E.T. Narayanan Mooss

Chairman and Managing Director Vaidyaratnam Oushadhasala Pvt. Ltd.

Dr. M.S. Valiathan

National Research Professor Manipal Academy of Higher Education

Prof. Ram Harsh Singh

Distinguished Professor Banaras Hindu University

Prof. Banwari Lal Gaur

Former Vice Chancellor DSRRAU, Jodhpur

Prof. K. Mohandas

Former Vice Chancellor Kerala University of Health Sciences

Dr. M.S. Baghel

Former Chairman Ayurveda Chair, University of Debrecan, Hungary

Publication Committee

Dr. P. Madhavankutty Varier

Chief Physician

Shri K.V. Ramachandran

Chief (Marketing)

Dr. T.S. Murali

Chief (Technical Services)

Dr. Indira Balachandran

Project Director, Centre for Medicinal Plants Research

Editorial Board

Dr. P. K. Mohanlal

Former Director Ayurveda Medical Education, Govt. of Kerala

Dr. P. Sankaran Kutty

Former Director Ayurveda Medical Education, Govt. of Kerala

Dr. M. P. Eswara Sarma

Principal

PNNM Ayurveda College, Cheruthuruthy

Dr. T. V. Sankarankutty

Former Professor VPSV Ayurveda College, Kottakkal

Dr. K. Murali

Professor

Govt. Ayurveda College, Kannur

Dr. T. Sreekumar

Professor

PNNM Ayurveda College, Cheruthuruthy

Dr. M. Prasad

Principal

Ashtamgam Ayurveda Vidyapeedham, Vavanoor

Dr. B. Syamala

Former Professor

Vaidyaratnam Ayurveda College, Ollur

Dr. Jose T. Paikada

Specialist Medical Officer Indian Systems of Medicine

Dr. M. V. Vinod Kumar

Associate Professor

VPSV Ayurveda College, Kottakkal

Chief Editor

Prof. K.G. Paulose







ISSN 0970 - 4086; Vol. XXXII, No. 3; February - April 2019

सतताध्ययनं वादः परतन्त्रावलोकनम् । तद्विद्याचार्यसेवा च बुद्धिमेधाकरो गणः ।।

Constant study, mutual discussion, learning other disciplines and serving the preceptor - these factors endow one with intelligence and memory

Details:

In India (inclusive of mailing): single copy, one hundred and twenty rupees; annual subscription (four issues) four hundred rupees. Out of India (postal charges extra) single copy, US dollars fifteen; annual subscription (four issues) US dollars fifty. Concessional rate for bonafide students of all systems of medicine in India, single copy, rupees ninety; annual subscription (four issues) rupees three hundred and twenty.

Please address all enquiries and subscriptions to: The Chief Editor (Publications), Arya Vaidya Sala, Kottakkal, Malappuram District, Kerala State, Pin - 676 503, India. Phone: 0483 -2742225, 2746665, Fax: 2742210, 2742572, E-mail: publications@aryavaidyasala.com.

Articles in this journal do not necessarily reflect the views or policies of the Arya Vaidya Sala. All material is protected by copyright and cannot be used in any manner without the permission of the respective authors and the Arya Vaidya Sala, Kottakkal.

Published by Department of Publications, Kottakkal Arya Vaidya Sala, Malappuram Dist. Kerala - 676 503, Phone: 0483 - 2742225, 2746665, Fax: 0483 - 2742210, 2742572, E-mail: publications@aryavaidyasala.com, Web: www.aryavaidyasala.com



CONTENTS

Anatomical and antihyperglycemic activity of Abutilon indicum L. Sweet (Atibalā) fruits	
Rajesh Bolleddu, Sama Venkatesh, Rao M. M. and Rachamalla Shyamsunder	05
A comparative pharmaceutico-analytical and in vitro anti-inflammatory study of aqueous and	
hydro-alcohol extracts of Rāsnāpañcaka kvāthaḥ	
Praveen M. and Harshitha M.	11
Study on Miśreya arka (Hydro distillate of Anethum graveolens L.) prepared by three	
different methods	
Shweta Paul, Karunanidhi Sharma, Sanjay Kumar and Parimi Suresh	20
A case study on healing effect of Apāmārga kṣāra (caustic therapy) in śalyajanya nāḍ̄i vraṇa after chedana karma	
Rajasree G. and Anita Patel K.	25
Management of jalodara vis-a-vis ascites with special reference to Jalodarāri rasa as virecana yoga	
Sanjay Kumar Giri and Sanghamitra Patnaik	31
Comparative X-ray fluorescence analysis of Kāsīsa purified by different methods	
Manali Anil Visaria and Sheela Pargunde	40
An approach to lifestyle disorders and its management in children	
Chethan Kumar V. K., Shubhangi Rathore and Harshitha M. S.	45

Toxicity profile of Malla sindūra- a kūpīpakva rasāyana	
Pallavi M., Pavan Kumar and Doddamani M. S	
PAGES FROM DHANVANTARI	
Kaṭukka (Harītakī)	
Cover image	
Reference to article, pages 05 to 10	

Ārvavaidvan, Vol. XXXII, No. 3, February - April 2019, Pages 05 - 10

Anatomical and antihyperglycemic activity of $Abutilon\ indicum$ L. Sweet (Atibalā) fruits

Rajesh Bolleddu, Sama Venkatesh, Rao M. M. and Rachamalla Shyamsunder

ABSTRACT: The present study was aimed to establish the antihyperglycemic properties of *Abutilon indicum* fruit by screening various fractions of hydro alcoholic extract of fruits. Anatomical and morphological parameters were studied as per Ayurvedic Pharmacopoeia. Antihyperglycemic studies were carried out by Glucose tolerance test. Toxicity studies were performed as per OECD 425 guidelines and all extracts were observed to be safe. Ethyl acetate fraction has shown significantly (p<0.01) highest hypoglycemic activity (34.83%) at a dose of 400mg/kg against glucose load of 2gm/kg, followed by ethanolic extract. Transverse section of fresh fruit showed the presence of glandular trichomes, stellate hairs and group of lignified palisade cells. The current anatomical studies can be considered as reference standard for future studies on *Abutilon indicum* fruits. The observed significant antidiabetic activity of fruits is an evidence for further studies.

Key words: Abutilon indicum, Transverse section, Anatomy, Fractionation, Antihyperglycemic activity

Introduction

Abutilon indicum (L.) Sweet belongs to the family Malvaceae, is an important medicinal plant used in āyurveda and is commonly called as 'atibalā'. It bears characteristic schizocarpic fruits, golden yellow flowers and is found throughout India. 1 Its bark is recommended as febrifuge, anthelmintic and alexeteric. In ayurveda, it is known to remove the vitiated conditions of vata and tridosa; allays thirst, vomiting and lessens perspiration.² Extracts from various parts of this plant has been reported to possess anticancer, anticonvulsant, antiasthmatic, antiestrogenic, antimicrobial, hepato-protective, hypoglycemic, immunomodulatory, analgesic and wound healing properties.³ Ethanolic extract of leaves have reported to possessing potent antibacterial⁴, antidiarrheal⁵ and immunomodulatory activity⁶. Like all other parts, fruits and seeds also reported considerable medicinal uses. Traditionally, fruits were used to treat piles, gonorrhea, cough, haemorrhagic septicemia and seed powder was used as aphrodisiac and laxative. Aqueous extract of seeds have been reported for its diuretic activity at 200 and 400mg/kg dose.⁸ Seed oil has been reported for its antibacterial and antioxidant activities.⁹ We have reported that the Ethyl acetate (86 mg GAE/g) and chloroform fraction (56 mg GAE/g) of fruits were found to contain high phenolic content and strong antioxidant potential.¹⁰ Phenolic compounds are known for hypoglycemic properties and the leaves of *A. indicum* were reported to possess antihyperglycemic activity.¹¹ As the fruits are rich in phenolic content, an attempt was made to assess the antihyperglycemic property of ethanolic extract and its fractions. Anatomical studies of fruits were performed for identification.

Materials and methodes

Collection of plant material: The fresh fruits of *A. indicum* were collected from Suryapet, Telangana, India. The plant authentication was done in Botanical Survey of India, Hyderabad. The voucher specimen (GPRCP/AI/BR12/2015) was maintained in the Department of Pharmacognosy, G. Pulla Reddy College of Pharmacy, Hyderabad. Fresh fruits were used for anatomical studies, shade dried fruits were used for hypoglycemic studies.

Anatomical studies: The free hand transverse sections of *A. indicum* fruits were first treated with chloral hydrate reagent, mounted in glycerine and observed for histological characters using compound microscope. Presence of lignified tissues were determined by treating the section with phloroglucinol and concentrated hydrochloric acid (1:1). Presence of starch was determined by treating with iodine solution. ^{1a, 12}

Preparation of ethanolic extract: The shade dried fruits powder (#60) was extracted with 80% ethyl alcohol by maceration for eight days. The percentage yield of aqueous ethanolic extract was 6.5 % w/w. ¹³

Fractionation of the mother extract: To the 100g of concentrated aqueous ethanolic extract, 500ml of distilled water was added and fractioned with petroleum ether (4X500ml), chloroform (4X500ml), ethyl acetate (4X500ml) and butanol (4X500ml). The percentage yield of petroleum ether, chloroform, ethyl acetate, butanol and left over fractions were 3.6, 1.4, 1.2, 3.7 and 74% respectively.¹⁴

Toxicity studies: Acute toxicity studies were done according to OECD 425 guidelines. The test used a maximum of 5 animals. A test dose of 2000 mg/kg was used. First animal was dosed and observed continuously for the initial period of 2hrs, intermittently for next 6 hrs and then 24 hrs for death and abnormality in behavioral changes. The animal survived. Then next four animals were dosed sequentially. All the animals survived- LD50 was>2000mg/kg.¹⁵

Test animals: Male wistar rats used in experiment were maintained under standard environmental conditions of temperature, relative humidity, dark/light cycles and free access to feed and water *ad libitum* during the quarantine period. The animals were fasted for 16 hrs before experimentation but had been allowed free access to water. All the extracts of *A. indicum* fruit were tested for glucose tolerance test at doses of 200 and 400 mg/kg and were

administered orally as fine aqueous suspension using 0.5% w/v carboxy methyl cellulose(CMC), as vehicle.

tolerance in rats: Overnight fasted rats were divided in 12 groups of 6 rats each. Group 1 was served as control, received vehicle. Group 2 to 11 received various CMC suspensions of *A. indicum* fruit extracts at an oral dose of 200 and 400 mg/kg. Group 12 received glibenclamide as standard at an oral dose of 10 mg/kg. After 30 min of extract administration, the rats of all groups were orally loaded with 2g/kg of glucose. Blood samples were collected from the retro orbital plexus just prior to glucose administration and at 30, 60 and 120 min after glucose loading. Plasma was separated and blood glucose levels were measured immediately by glucose-oxidase method. 16,17,18

The percentage variation of glycaemia was calculated for each group using the formula:

Percent variation in glycaemia = Gi-Gt/Gi X 100

Where, Gi- value of initial glycemia (0 hour) and Gt- glycemia at 30, 60 and 120min respectively.

Statistical analysis: All the values were expressed as mean ± SEM. Results were analyzed statistically by using analysis of variance (ANOVA) followed by Dunnett's test. Values of P<0.05 were considered significant.

Results and discussion

Morphological characters: Fresh fruits of *A. indicum* are green in colour, shizocarpic, circular in shape, consisting of 11-16 radiating densely pubescent mericarp per fruit, each mericarp flattened, somewhat boat shaped, black when ripe 1-2 cm in diameter consist of 2-3 seeds. Seeds were reniform, hairy, dotted, minutely scrobiculate, brownish black in colour and 3-5mm diameter. Odour characteristic; taste bitter. Figure 1.

Figure 1


Abutilon indicum fruits (Fr) and seeds (Sd)



Anatomical characters: Fruit mericarp transverse section showed group of stellate hairs, glandular covering trichomes with multicellular uniseriate stalk with collapsed cells and unicellular globular head. Lignified irregular shaped endocarp cells, groups of fusiform lignified sclerenchymatous fibers running wavy crossing each other, presence of xylem vessels was also observed. Figure 2.

Transverse section of seed showed the presence of oval shaped cells of testa with lignified stroma and warty epidermis covered with cuticle. A narrow parenchymatous cell layer of hypodermis was located underneath this, followed by a layer of lignified palisade cells. Centrally located endosperm embedded with 'U' shaped embryo with their free

Figure 2
Transverse section of *Abutilon indicum* fruit mericarp



Gt- Glandular trichome; Epi- Epicarp; Sh- Stellate hair; Mc-Mesocarp; Ec- Endocarp; Sl-Sclerenchymatous layer


terminals pointing towards the hilar edge was noticed. Inside lumen was loaded with aleurone grains and few oil globules. Figure 3.

Toxicity studies

In oral acute toxicity studies, no mortality and

abnormal behavioral changes observed in mice up to a dose of 2 g/kg body weight. All extracts of *A. indicum* was considered to be safe and further antihyperglycemic activity was tested at an oral dose of 200 and 400 mg/kg body weight.

Figure 3
Transverse section of *Abutilon indicum* seed



Sc-Seed coat (Testa); St- Stroma; Ep- Epidermis; Hyp- Hypodermis; Psd-Palisade cells; End-Endosperm; Emb-Embryo; Oil-Oil globule; Alg- Aleurone grains

Effect of *A. indicum* **fruit extracts on glucose tolerance in rats**: The effect of *A. indicum* extracts in glucose tolerance test is given in Table 1. All extracts produced antihyperglycemic properties. However, the ethyl acetate and aqueous ethanolic extracts produced a significant (p<0.01) dose dependent activity when tested at 200 and 400 mg/kg dose. The animals that received 400 mg/kg showed maximum activity at 60 min after glucose administration. Ethyl acetate extract at a dose of 400 mg/kg produced maximum protection (34.83%) followed by aqueous ethanolic extract and butanolic

extract at 60 min after glucose administration. The activity produced by the extracts are not comparable with standard glibenclamide activity at the time of experiment. The standard glibenclamide (10 mg/kg) produced a significant maximum protection at 60 min (60.29%). Left over aqueous extracts did not produce any considerable antihyperglycemic properties. The percentage protection of ethanolic, petroleum ether, chloroform, ethyl acetate and butanol extracts at 60 minutes was 26.98, 7.74, 22.75, 34.83, and 24.16 respectively, when tested at 400mg/kg dose.

8

	Table 1						
	Effect of A. indicum fruit extracts on glucose tolerance in rat						
Group	Treatment	Dose mg/kg	Fasting	30min	60min	120min	
1.	Control		73.58 <u>+</u> 1.39	114.79 <u>±</u> 1.04	167.37±1.21	113.14 <u>±</u> 1.36	
2.	Aq. Et. Ext.	200	65.70±1.4**	109.43±1.33* (4.66)	140.78±1.09** (15.88)	104.16±1.14** (7.93)	
3.	Aq. Et. Ext.	400	71.55±1.25**	102.81±1.39** (10.43)	122.2±1.3** (26.98)	102.16±1.4** (9.7)	
4.	Pet. Eth. Ext.	200	69.67 <u>+</u> 0.88**	110.95±1.36** (3.34)	158.34±1.02** (5.39)	109.47±0.99** (3.24)	
5.	Pet. Eth. Ext.	400	67.56 <u>±</u> 1.37**	107.26±1.38 (6.55)	154.41±1.22** (7.74)	106.86±1.23** (5.55)	
6.	Chloroform Ext.	200	72.08 <u>+</u> 0.81**	98.81±1.25** (13.92)	138.2±1.3** (17.42)	95.66±1.38** (15.44)	
7.	Chloroform Ext.	400	72.68 <u>+</u> 1.36**	96.88±1.3** (15.6)	129.29±1.27** (22.75)	92.96±1.08** (17.83)	
8.	Ethyl Ac. Ext.	200	70.11 <u>+</u> 0.95**	92.09±1.04** (19.78)	113.41±1.43** (31.44)	86.8±1.41** (23.28)	
9.	Ethyl Ac. Ext.	400	72.38 <u>+</u> 0.87**	85.16±1.41** (25.81)	109.07±1.21** (34.83)	81.2±1.26** (28.23)	
10.	Butanolic Ext.	200	69.11±1.37*	99.56±1.23** (13.26)	131.41±1.43** (21.48)	107.02±1.15** (5.4)	
11.	Butanolic Ext.	400	68.83 <u>±</u> 1.43**	97.69±1.26** (14.89)	126.92±1.23** (24.16)	99.68±1.17** (11.89)	
12.	Glibenclamide	10	70.15±0.21**	62.92±0.46** (45.18)	66.46±0.94** (60.29)	53.37±0.46** (52.82)	

Aq. Et. Ext. - Acquous ethanolic extract; Pet. Eth. Ext. Petroleum ether extract; Ethyl Ac. Ext.- Ethyl acetate extract;

Conclusion

For the first time, antihyperglycemic properties of *Abutilon indicum* fruits were reported. Among all fractions ethyl acetate fraction (34.83%) and ethanolic extract (26.98%) showed the highest therapeutic activity at 400 mg/kg dose. This scientific evidence will help the researchers to explore further at higher animal models to develop a clinical candidate for the treatment of diabetes. The presence of stellate hairs and glandular covering trichomes are the diagnostic characters for identification of fruits. Whereas, the presence of lignified palisade cells and 'U' shaped embryo are important characters in anatomy of seeds. These anatomical studies can be considered as reference standards for future studies.

References

- 1. The Ayurvedic Pharmacopoeia of India, 1(1): P 25-26, Department of Indian Systems of Medicine and Homeopathy, New Delhi, 1992.
- 1a. Ibidem., 1(1):P 142-143
- 2. Kirtiar K. R. and Basu B. D., *Indian Medicinal Plants*, P 314-317, 2nd Edition, Dehradun, 1994.
- 3. Rajagopal Ramasubramania Raja and Koumara Velou Kailasam, *Abutilon indicum* L. (Malvaceae)- Medicinal potential review, *Pharmacognosy Journal*, 7(6): P 330-332, 2015.
- 4. Poonkothai M., Antibacterial activity of leaf extract of *Abutilon indicum, Ancient Science of Life*, XXVI 1and 2, 2006.
- 5. Chandrashekhar V. M., Nagappa A. N., Channesh T. S., Habbu P. V. and Rao K. P., Anti-diarrhoeal activity of *Abutilon indicum* Linn. leaf extracts, *Journal of Natural Remedies*, 4(1): P 12-16, 2004.

- 6. Dashputre N. L. and Naikwade N. S., Immunomodulatory activity of *Abutilon indicum* Linn. on albino mice, *International Journal of Pharma Sciences and Research*, 1(3), P 178-184, 2010.
- 7. Kaushik P., Kaushik D., Khokra S. and Chaudhary B., *Abutilon indicum* (Atibala): Ethno-botany, phytochemistry and pharmacology- a review, *International Journal of Pharmaceutical and Clinical Research*, 1(1): P 4-9, 2009.
- 8. Gunasekaran Balamurugan, Shinnaraj Seivarajan, Dhanapal Balakrishnan and Palayan Muralidharan, Diuretic activity of *Abution indicum* Linn. Sweet seed extract, *Journal of Herbal Medicine and Toxicology*, 4(1): P 49-52, 2010.
- 9. Muhammad Akram Kashmiri, Sammia Yasmin, Mushtaq Ahmad and Ayesha Mohy-ud-Din, Characterization, compositional studies, antioxidant and antibacterial activities of seeds of *Abutilon indicum* and *Abutilon muticum* grown wild in Pakistan, *Acta Chimica Slovenica*, 5(6): P 345-352, 2009.
- 10. Rajesh Bolleddu, Sama Venkatesh, Azmathunnisa Begum, Ravi Alvala and Rachamalla Shyamsunder, Bioguided extraction and evaluation of antioxidant studies of *Abutilon indicum* fruits, *Journal of Biomedical and Pharmaceutical Research*, 5(6): P 68-74, 2016.
- 11. Pawan Kaushik, Dhirender Kaushik, Sukhbir Lal Khokra and Anil Sharma, Antidiabetic activity of the plant *Abutilon indicum* in streptozotocin induced experimental diabetes in rats, *International Journal of Pharmacognosy and Phytochemical Research*, 2(2); P 45-49, 2010.

- 12. Rajesh Bolleddu *et. al.*, Establishment of quality parameters for leaf, stem and root of *Sonchus wightianus* DC. through pharmacognostical standardization, *International Journal of Pharma Research and Heal th Sciences*, 6 (1): P 2290-94, 2018.
- 13. Sama V. et al., Evaluation of antioxidant potential of *Caralluma attenuata*, *Indian Drugs*, 50(04): P 26-33, 2013.
- 14. Patel D.K., Kumar R., Laloo D. and Hemalatha S., Evaluation of phytochemical and antioxidant activities of the different fractions of *Hybanthus enneaspermus* (Linn.) Muell F. (Violaceae), *Asian Pacific Journal of Tropical Medicine*, 4(5):P 391-396, 2011.
- 15. Gosh M.N., Fundamentals of experimental pharmacology, P 177, Scientific Book Agency, Kolkata, India, 1984.
- 16. Sachdewa A. *et al.*, Effect of *Aegle marmelos* and *Hibiscus rosa-sinensis* leaf extract on glucose tolerance in glucose induced hyperglycemic rats, *Journal of Environmental Biology*, 22(1): P 53-57, 2001.
- 17. Srujana M., Ramesh R. and Nanjaiah L.D., Antidiabetic potential of active fraction obtained from methanolic extract of *Ichnocarpus frutescens*: A possible herbal remedy, *Indian Journal of Pharmacology*, 50(5):P 251-259, 2018.
- 18. Renjit Bino Kingsley, Manisha Mishra, Pemaiah Brindha and Appian Subramoniam, Anti-diabetic activity of active fractions of *Stereospermum tetragonum* DC. and isolation of active principles, Journal of Young Pharmacists, 5(1):P 7-12, 2013.

Authors

Rajesh Bolleddu, Central Ayurveda Research Institute for Drug Development, CCRAS, Ministry of AYUSH, Kolkata, West Bengal-700 091, India.

Sama Venkatesh, G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-500 028, Telangana, India.

Rao M. M., Central Ayurveda Research Institute for Drug Development, CCRAS, Ministry of AYUSH, Kolkata, West Bengal-700 091, India.

Rachamalla Shyamsunder, Faculty of Pharmacy, University College of Chemical Technology, Osmania University, Hyderabad, Telangana, India.

Āryavaidyan, Vol. XXXII, No. 3, February - April 2019, Pages 11 - 19

A comparative pharmaceutico-analytical and in vitro anti-inflammatory study of aqueous and hydro-alcohol extracts of Rāsnāpañcaka kvāthaḥ

Praveen M. and Harshitha M.

ABSTRACT: Scarcity of raw materials is a major problem faced in āyurveda. Maximum extraction (herb-to-extract ratio) from the limited available raw materials without compromising the potency and minimize the extractive value in the residue is one of the solutions to surmount the problem. The extraction using 50% aqueous alcohol as solvent is being employed in this view. The fact that constituents that are insoluble in water may be soluble in alcohol and vice versa, may contribute to the enhanced potency, favors the industry for hydro-alcohol extraction. This has to be tested for each formulation. Potency and efficacy being important parameters, pre-clinical analysis of formulations includes pharmaceutical and *in vitro* tests besides the biological studies. HPTLC (High performance thin layer chromatography) is one of the methods to assess the potency of a drug pharmaceutically. Protein denaturation inhibition using bovine serum albumin is an *in vitro* method to assess the efficacy of a drug through its anti-inflammatory activity. Taken as the investigational product, Rāsnāpañcaka kvāthaḥ, the aqueous and the hydro-alcohol extracts of this formulation were tested and compared for its potency and anti-inflammatory efficacy by HPTLC and *in vitro* protein denaturation inhibition assay respectively. The results showed improved performance of hydro-alcohol extract of this formulation pharmaceutically as well as efficaciously.

Key words: Rasnāpañcaka kvāthah, HPTLC, Protein denaturation inhibition assay

Introduction

Āyurveda, as a medical science, is evolved from the health needs of the society in the course of time. The evolution is visible in every field of āyurveda like preparation of medicines, development of new branches, approaches to diseases, etc. The very existence of āyurveda in the modern world as an independent and complete medical science is mainly due to its strong foundation in theories and principles and its adaptability to accept knowledge and ideas from contemporary sciences. Every science needs to be updated and revalidated frequently to keep pace with changing times for its existence. Āyurveda is no exception.

Perhaps, bhaiṣajyakalpana, pharmaceutics is one of the areas āyurveda has undergone tremendous change or development since its inception. The knowledge of conversion of raw materials into the desirable dosage forms is crucial in any medical science. Newer dosage forms evolved are brought into the practice to meet the health needs of the society. Preparations like avaleha, vaṭi, sneha and sandhānakalpana, etc. stands testimony to the efforts to make a drug more acceptable and make them available all seasons. Different dosage forms are introduced in the view of better extractive value, potency and shelf life besides better therapeutic efficacy and user friendliness.

Ayurveda is crucially dependant on the uninterrupted availability of raw materials of good quality in the right quantity. About 80% of the raw materials come from the vegetable kingdom both in fresh and dried forms. The demands for the herbal medicines are on the increase globally. This leads to severe scarcity of raw materials, especially of herbal origin. The need for their manufacture in bulk under industrialized and commercialized scenario has necessitated proper methodology for their scientific standardization.

Maximum extraction (herb-to-extract ratio) and thus minimize the extractive value in the residue is one of the solutions for the major problem of scarcity of raw materials in āyurveda. Increasing the yield of medicinal formulations to maximum from the available limited raw materials without compromising the potency is the need of the hour. Many newer techniques of extractions, such as solvent extraction, super critical extractions, etc. are being employed in the āyurveda medicine manufacturing industry now a days.

The Government of India has legalized the usage of 50% aqueous alcohol in the āyurveda medicine manufacturing industry for the extraction. The fact that many constituents that are insoluble in water may be soluble in alcohol and vice versa, may enhance the potency of such extract. The advantages of hydroalcoholic extracts compared to aqueous extract are many, namely, enhanced potency, more yield, minimum wastage, reduction in the usage of raw materials, reduction in bulk of dosage form and convenience in administering doses. But this advantage has to be ensured for each formulation by testing it phyto-chemically as the yield of extraction and potency varies from drug to drug and formulation to formulation.

Pre-clinical analysis of formulations includes pharmaceutical and *in vitro* studies besides biological studies. High performance thin layer chromatography (HPTLC) is one of the methods to assess a drug pharmaceutically. Protein denaturation inhibition using bovine serum albumin is an *in vitro* method to assess the efficacy of a drug through its antiinflammatory activity.

Rāsnāpañcaka kvāthaḥ, mentioned in Cakradatta² is indicated in sāmavāta affecting sandhi, asthi and majja. Most of its ingredients possess an anti-inflammatory activity.

This study is an attempt to compare and analyze the potency and efficacy of both the aqueous and hydro-alcohol extracts of Rāsnāpañcaka kvāthaḥ yoga pharmaceutically and by *in vitro* method by protein denaturation inhibition for its anti-inflammatory activity.

Objectives

- To prepare aqueous and hydro-alcohol extracts of Rāsnāpañcaka kvāthah.
- To carry out comparative pharmaceutico-analytical study of both the samples.
- To carry out comparative *in vitro* anti-inflammatory study by protein denaturation inhibition method.

Review of literature

Rāsnāpañcaka kvāthaḥ: The present study was based on Rāsnāpañcaka kvāthaḥ yoga. This formulation is mentioned in Cakradata in āmavātacikitsā. The classic treatises like Bhāvaprakāśaḥ³, Yogaratnākaraḥ⁴, Bhaiṣajyaratnāvalī⁵, Śāraṅgadharasamhitā⁶ and the classical compendium of formulations in Malayalam, Sahasrayogam² also mention the formulation. The ingredients have the anti-inflammatory action. Tables 1 and 2 gives the basic information about the formulation.

	Table 1 Rāsnāpañcaka kvāthaḥ ingredients, botanical identity and their ratio						
Drug	Botanical name	Family	Part used	Quantity			
Rāsnā	Alpinia galanga (L.)Willd.	Zingiberaceae	Rhizome	1 part			
Guḍūcī	Guḍūcī Tinospora sinensis (Lour.) Merr. Menispermaceae Stem 1 part						
Eraṅḍa	Ricinus communis L.	Euphorbaceae	Root	1 part			
Devadāru	Devadāru <i>Cedrus deodara</i> (Roxb. ex. D. Don) G.Don Pinaceae Heart wood 1 part						
Śuṇṭhī	Zingiber officinale Roscoe	Zingeberaceae	Rhizome	1 part			

Taryavaidyan Aryavaidyan

Table 2 Rasapañcaka of Rāsnāpañcaka kvāthaḥ as per Bhāvaprakāśa							
Ingredients	Ingredients Rasa Guṇa Virya Vipāka Karma						
Rāsnā	Tikta	Guru	Uṣṇa	Kaṭu	Amapācana		
Guḍūcī	Tikta, kaṣāya	Guru, snigdha	Uṣṇa	Madhura	Amapācana		
Eraṅḍa	Madhura	Snigdha,tīkṣṇa	Uṣṇa	Madhura	Amapācana		
Devadāru	Tikta	Laghu, snigdha	Uṣṇa	Kaṭu	Amapācana		
Śuṇṭhī	Kaṭu	Laghu, snigdha	Uṣṇa	Madhura	Amapācana		

Protein denaturation inhibition assay:

Denaturation of proteins is a well documented cause of inflammation. The bonding of a protein can easily be disrupted by a variety of physical and chemical agents as it is dependent on weak valence forces. The process is known as denaturation. The organized structure will lose and the protein assumes a highly disordered form. The protein will mislay its biological activity. Many globular proteins render less soluble on denaturation. Moist heat is a powerful denaturing agent. Extremes of acidity and alkalinity at moderate temperatures can disrupt the structure of proteins.

The compounds that inhibit the denaturation of proteins *in vitro* may be used as anti-inflammatory agents.⁸ The anti-inflammatory effect of a sample can be performed by using bovine serum albumin (BSA). BSA assay seeks to eliminate the use of live specimens as far as possible in the drug development process. When BSA is heated, it undergoes denaturation (heat induced protein denaturation) and express antigens associated with type 3 hypersensitivity reactions, which can be related to the inflammation.

The anti-inflammatory efficacy of a drug can be expressed in terms of half maximal inhibition concentration (IC₅₀). It is a measure of the potency of a substance in inhibiting a specific biological or biochemical function. This quantitative measure indicates how much of a particular drug or other substance (inhibitor) is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganisms) by half. The values are typically expressed as molar

concentration. The lower the IC_{50} value, the stronger the inhibitor is.

Materials and methods

For ease of understanding, the present work is categorized in three steps namely:

- 1. Pharmaceutical study
- 2. Analytical study
- 3. In vitro anti-inflammatory study
- **1. Pharmaceutical study**: This involves the following steps;
- a) Identification, collection and authentication of raw materials of the investigational product.
- b) Preparation of aqueous and hydro-alcohol extracts of Rāsnāpañcaka kvāthah yoga.
- a) Collection and authentication of raw materials: Raw materials of Rāsnāpañcaka kvāthaḥ yoga were collected locally from Kottakkal, Kerala. The authentication of all the raw drugs was done at Center for Medicinal Plants Research Center, Arya Vaidya Sala, Kottakkal, Malappuram District, Kerala (CMPR).
- b) Preparation of aqueous extract of Rāsnāpañcaka kvāthaḥ: Rāsnāpañcaka kvāthaḥ was prepared by conventional method. The washed and coarse powdered ingredients (200 grams each) were boiled under a controlled temperature in 16 liters of water to reduce to 1/8th (2 liters). The strained kvāthaḥ was then concentrated using mild heat till the liquid turns to paste or syrupy consistency. This was made into dry solid mass by dry heating it in a vacuum drier. The resultant dry powder, the aqueous

Āryavaidyan [13]

extract- was stored air tight for further analytical tests and *in vitro* study.

- c) Preparation of hydro-alcohol extract of Rāsnāpañcaka kvāthah: Hydro-alcohol extract of Rāsnāpañcaka kvāthah yoga was prepared as per the guidelines of The Ayurveda Pharmacopoeia of India (API). The washed and coarse powdered ingredients (200 grams each) were extracted with 3000 ml of 50% aqueous alcohol under reflux at a temperature between 80-85°C for 3-4 hours using water bath. The extract was then strained. The marc was extracted three times more, filtering the extract each time into the same vessel. The combined filtrate was then concentrated using water bath to syrupy constituency. This was made into a dry mass by heating in a vacuum drier to eliminate the moisture content fully. The resultant dry powder, the hydro-alcohol extract- was stored air tight for further analytical tests and in vitro study.
- **2. Analytical study**: The analytical evaluation of the samples was carried out at AYUSH accredited R. and D. Laboratory of Arya Vaidya Sala, Kottakkal, Malappuram, Kerala. The samples prepared were

analyzed as per the guidelines of CCRAS.¹⁰ The following analytical parameters were tested and tabulated.

- Organoleptic characters
- pH
- Loss on drying (LOD)
- Water soluble extractive
- Alcohol soluble extractive
- Ash value
- Acid insoluble ash
- HPTLC
- **3.** *In vitro* **anti-inflammatory study**: The samples prepared were studied for their anti-inflammatory activities by protein denaturation inhibition capability, at Biogenix Research Center, using bovine serum albumin. Heat was used to denature the protein.

Diclofenac sodium was used as standard solution. Different concentrations of samples such as $62.5\mu g/ml$, $125\mu g/ml$, $250\mu g/ml$ and $500\mu g/ml$ prepared from a stock solution of 10 mg/ml were used for the study. The details of the solutions prepared are summarized in Table 3.

Table 3

Technical details of test solutions

Test Solution (0.5 ml): 0.05 ml of test solution + 0.45 ml of BSA (5% aqueous solution)

- Test solution 1: 0.05 ml of aqueous extract (AE) + 0.45 ml of BSA
- Test solution 2: 0.05 ml of hydro-alcoholic extract (HAE) + 0.45 ml of BSA

Test Control Solution (0.5 ml): 0.05 ml of distilled water + 0.45 ml of BSA

Product Control Solution: 0.05 ml of test solution + 0.45 ml distilled water.

- Product control solution 1: 0.05 ml of test solution 1 + 0.45 ml of distilled water.
- Product control solution 2: 0.05 ml of test solution 2 + 0.45 ml of distilled water.

Standard Solution (0.5 ml): 0.05 ml of diclofenac sodium + 0.45 ml of BSA.

All the solutions were adjusted to pH 6.3 using 1N HCl. The samples were incubated at 37°C for 20 minutes and the temperature was increased to 57°C for 3 minutes. After cooling, 2.5 ml of phosphate buffer was added to the solutions. The absorbance

was measured using UV-Visible Spectrophotometer at 416 nm.

The percentage inhibition of protein denaturation of each of the trial drug was calculated using the following formula.

Taryavaidyan Aryavaidyan

Percentage of inhibition = $100 - [(OD_{TS} - OD_{PC}) \div (OD_{TC})] \times 100$.

OD, the optical density is measured by spectrophotometry.

The test was repeated thrice for the confirmation and the results were tabulated. The IC_{50} values of the investigational products were calculated using ED50 Plus V1.0 software and were tabulated.

Observations and results

The samples are represented by AE and HAE for aqueous and hydro-alcohol extracts of Rāsnāpañcaka kvāthaḥ yoga respectively.

Table 4 Organoleptic characters of AE and HAE						
Characters/ parameters	AE	HAE				
Physical appearance powder	Coarse powder	Coarse				
Colour	Dark brown	Dark brown				
Odour	Smell of ginger	Smell of ginger				
Taste	Kaṣāya, kaṭu	Kaṣāya, kaṭu				
Touch	Rigid	Rigid, sticky				

The observed results of the physico-chemical tests are given in Table 4 and 5. The results of HPTLC are tabulated in Table 6 and 7 and in Figure 1 and 2. The observed values of *in vitro* anti-inflammatory activity of the samples by protein denaturation inhibition method are given in Table 8 and 9. The calculated IC_{50} values are enumerated in Table 10.

	Table 5 Observed values of physico-chemical analysis							
No.	Parameters	Unit	AE	HAE				
1.	LOD	% w/w	2.96	1.26				
2.	2. pH of 10% solution of							
	content	-	6.8	5.5				
3.	Water soluble extractive	% w/w	67.51	47.99				
4.	Alcohol soluble extractive	% w/w	16.28	43.58				
5.	Total ash	% w/w	29.07	12.44				
6.	Acid insoluble ash	% w/w	BDL	BDL				

	Table 6 Area and Peaks of AE and HAE at 254 nm					
Peak		AE			HAE	
	Rf value	Area (AU)	% Area (AU)	Rf value	Area (AU)	% Area (AU)
1.	0.06	204.4	0.71	0.05	302.3	0.55
2.	0.15	4787.5	16.63	0.14	5072.0	9.18
3.	0.25	1435.7	4.99	0.24	768.9	1.39
4.	0.27	259.4	0.90	0.27	865.4	1.57
5.	0.32	4826.5	16.76	0.32	3246.8	5.88
6.	0.36	785.0	2.73	0.37	1135.9	2.06
7.	0.43	320.6	1.11	0.43	835.2	1.51
8.	0.48	3097.8	10.76	0.49	1484.3	2.68
9.	0.61	12148.7	42.20	0.54	2463.6	4.46
10.	0.77	925.1	3.21	0.65	33711.9	61.01
11				0.76	5366.9	9.71

Table 7 Summary of peaks and area under the curve					
AE HAE					
Total peak no.	10	11			
Total area in AU	28790.7	55253.2			

Table 8 Observed values of OD of Diclofenac sodium standard in spectrometry						
Concentrations (µg/mL)	OD of TS	OD of PC	% of inhibition			
Triplicate I: A	Absorbance of	test control: (0.0243			
62.5	0.0257	0.0064	20.58			
125	0.0468	0.0370	59.67			
250	0.0878	0.0811	72.43			
500	0.1266	0.1245	91.36			
Triplicate II: A	Absorbance of	f test control:	0.0252			
62.5	0.0263	0.0070	23.41			
125	0.0488	0.0384	58.73			
250	0.0872	0.0821	79.76			
500	0.1253	0.1237	93.65			
Triplicate III:	Triplicate III: Absorbance of test control: 0.0268					
62.5	0.0307	0.0101	23.13			
125	0.0498	0.0376	54.48			
250	0.0911	0.0832	70.52			
500	0.128	0.1262	93.28			

Table 10 IC ₅₀ values calculated				
Investigational product	IC50			
AE	312.229µg/mL			
HAE	285.209µg/mL			
Diclofenac sodium	109 µg/mL			

Concentrations OD of OD of of of of on on on on				
AE and HAE in spectrometry Concentrations (μg/mL) OD of TS OD of einhibition % of inhibition Triplicate I: Absorbance of test control: 0.0267 Sample code: AE 62.5 0.0281 0.0072 21.72 125 0.0472 0.0299 35.21 250 0.0829 0.0687 46.82 500 0.1017 0.0925 65.54 Sample code: HAE 62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 </td <td></td> <td>Table 9</td> <td></td> <td></td>		Table 9		
Concentrations (μg/mL) OD of TS OD of PC inhibition % of inhibition Triplicate I: Absorbance of test control: 0.0267 Sample code: AE 62.5 0.0281 0.0072 21.72 125 0.0472 0.0299 35.21 250 0.0829 0.0687 46.82 500 0.1017 0.0925 65.54 Sample code: HAE 62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 <td></td> <td></td> <td></td> <td></td>				
TS		-		
Triplicate I: Absorbance of test control: 0.0267 Sample code: AE 62.5				
Sample code: AE 62.5 0.0281 0.0072 21.72 125 0.0472 0.0299 35.21 250 0.0829 0.0687 46.82 500 0.1017 0.0925 65.54 Sample code: HAE 62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 <t< td=""><td>•</td><td></td><td></td><td></td></t<>	•			
62.5 0.0281 0.0072 21.72 125 0.0472 0.0299 35.21 250 0.0829 0.0687 46.82 500 0.1017 0.0925 65.54 Sample code: HAE 62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146				0.0267
125				21.72
250 0.0829 0.0687 46.82 500 0.1017 0.0925 65.54 Sample code: HAE 62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5				
500 0.1017 0.0925 65.54 Sample code: HAE 62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125				
Sample code: HAE 62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250				
62.5 0.0468 0.0234 12.36 125 0.0642 0.0443 25.47 250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43<				65.54
125				
250 0.0921 0.0800 54.68 500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5			0.0234	
500 0.1121 0.1052 74.16 Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125	125	0.0642	0.0443	25.47
Triplicate II: Absorbance of test control: 0.0289 Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	250	0.0921	0.0800	54.68
Sample code: AE 62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	500	0.1121	0.1052	74.16
62.5 0.0301 0.0085 25.26 125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	Triplicate II: Al	osorbance of	test control:	0.0289
125 0.0520 0.0329 33.91 250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	5	Sample code:	AE	
250 0.0792 0.0632 44.64 500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	62.5	0.0301	0.0085	25.26
500 0.0993 0.0889 64.01 Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	125	0.0520	0.0329	33.91
Sample code: HAE 62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	250	0.0792	0.0632	44.64
62.5 0.0521 0.0274 14.53 125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	500	0.0993	0.0889	64.01
125 0.0699 0.0493 28.72 250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	S	ample code:	HAE	
250 0.0984 0.0880 64.01 500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	62.5	0.0521	0.0274	14.53
500 0.1218 0.1146 75.09 Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	125	0.0699	0.0493	28.72
Triplicate III: Absorbance of test control: 0.0282 Sample code: AE 62.5	250	0.0984	0.0880	64.01
Sample code: AE 62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	500	0.1218	0.1146	75.09
62.5 0.0296 0.0118 29.92 125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	Triplicate III: A	bsorbance of	test control:	0.0282
125 0.0486 0.0321 35.04 250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33		Sample code:	AE	
250 0.0818 0.0687 48.43 500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	62.5	0.0296	0.0118	29.92
500 0.0973 0.0889 66.93 Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	125	0.0486	0.0321	35.04
Sample code: HAE 62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	250	0.0818	0.0687	48.43
62.5 0.0558 0.0329 9.84 125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	500	0.0973	0.0889	66.93
125 0.0846 0.0662 27.56 250 0.0987 0.0871 54.33	S	ample code:	HAE	
250 0.0987 0.0871 54.33	62.5	0.0558	0.0329	9.84
	125	0.0846	0.0662	27.56
500 0.1255 0.1100 74.41	250	0.0987	0.0871	54.33
500 0.1255 0.1190 74.41	500	0.1255	0.1190	74.41

Taryavaidyan Taryavaidyan





Figure 1

Overview graph of samples at various wave lengths

Figure 2
TLC Plate views of AE and HAE



Discussion

Scarcity of raw materials is a major problem faced in āyurveda. Maximum extraction (herb-to-extract ratio) from the limited available raw materials and thus minimize the extractive value in the residue is one of the solutions to the problem. Increasing the yield of medicinal formulations to maximum from the available limited raw materials without

compromising the potency is the need of the hour. Newer extraction methods are experimented in the industry with this purpose. The extraction using 50% aqueous alcohol as solvent is one of them. The assumed better potency of the hydro-alcohol extract has to be tested for each formulation.

Taken as the investigational product, Rāsnāpañcaka kvāthaḥ, the aqueous and the hydro-alcohol extracts

of this formulation were tested and compared for its pharmaceutical potency and anti-inflammatory efficacy by HPTLC and *in vitro* protein denaturation inhibition assay respectively.

The extracts prepared show no visible difference. The yield of the extracts from 1 kg of raw materials is 95 grams for aqueous and 85 grams for hydro-alcohol extract.

All the physico-chemical values are compatible for both extracts. Hydro-alcohol extract is slightly acidic for its significance is not explored in the present study. Acid insoluble ash value of both extracts is below the detection level which indicates the absence of any foreign particles.

The HPTLC test in the present study was intended in view to analyze and compare the pharmaceutical potency of the samples. Profiles of both extracts were compatible. Both the samples have similar peaks, though hydro-alcohol extract has a small additional peak at Rf 0.54 (2463.6 AU of area). HAE has an area under the curve of 55253.2 AU whereas AE has only an area under the curve of 28790.7 AU.

The anti-inflammatory efficacy of a drug can be expressed in terms of half maximal concentration (IC $_{50}$) by calculating the percentage of inhibition. The lower the IC $_{50}$ value, the stronger the inhibitor is. IC $_{50}$ of AE is 312.229 $\rm \tilde{n}g/mL$ and that for HAE, it is 285.209 $\rm \tilde{n}g/mL$.

Conclusion

Based on the findings and the discussion, it is concluded that:

- There are no notable organoleptic differences between these extracts. All the physico-chemical indices are compatible for both extracts.
- The hydro-alcohol extract of Rāsnāpañcaka kvāthaḥ has more pharmaceutical potency and anti-

inflammatory activity compared to its aqueous extract evidenced by chromatography and *in vitro* protein denaturation inhibition assay.

Scope for further study

- Safety profiling of the products by toxicological study
- Suitable *in vivo* animal study to substantiate the efficacy of the product.
- Clinical trial to substantiate the efficacy o the product on humans.

Acknowledgements

I acknowledge Dr. N.S. Shettar, Prinicipal, Dr. Rohini D. Bharadwaj, HOD, Dr. Purushotham K.G., Professor and Dr. Rohith Krishnan G.B, Department of Rasasastra and Bhaishajyakalpana, KVG Ayurveda College, Sullia, Dr. E.M. Anandan, Dr. K. Devikrishnan, Mr. Rajesh S. Mony and Mr. Harikrishnan of Arya Vaidya Sala, Kottakkal, Mr. Rajesh Ramachandran and his team at Biogenix Research Center, Trivandrum, for their guidance and relentless support.

References

- 1. *The Gazette of India*, Extra ordinary Part II section 3, Sub section (i), Ministry of Health and Family Welfare, Department of AYUSH Notification: GSR 663 (E) dated August 10, 2010.
- 2. Cakrapanidatta, *Cakradatta*, edited by Sharma P.V., 25/7, P 228, I edition, Chaukhambha Orientalia, Varanasi, 1994.
- 3. Acarya Bhavamisra, *Bhavaprakasa*, edited by Brahma Sankara Misra, Part II, 26/40, P 285, 5th Edition, Chaukhambha Sanskrit Sansthan, Varanasi, 1988.
- 4. *Yogaratnakara*, Edited by Sadasiva Sastri Joshi, P 443, First Reprint, Chaukhambha Sanskrit Series, Varanasi, 1939.
- 5. Govindadasa, *Bhaishajyaratnavali*, edited by Ambikadatta Sastri, 29/24, P 435, 2nd Edition, Chaukhambha Sanskrit Series, Varanasi, 1961.

Taryavaidyan Aryavaidyan

- 6. Acarya Sarangadhara, *Sarangadharasamhita*, edited by Srikanta Murthy K.R., Madhyama Khanda 2/85, P 66, First Reprint Edition, Chaukhambha Orientalia, Varanasi, 2017.
- 7. *Sahasrayogam* (Malayalam) with the Sujanapriya Commentary, edited by Krishnan Vaidyan K.V., P 83, 27th Edition, Vidyarambham Publishers, Alappuzha, 2007.
- 8. Mizushima Y. and Kobayashi M., Interaction of antiinflammatory drugs with serum proteins, especially with some
- biologically active proteins, *Journal of Pharmacy and Pharmacology*, March 1; 20(3):169-73, 1968.
- 9. *The Ayurvedic Pharmacopoeia of India*, Part I, Vol. VIII, First Edition, CCRAS, Ministry of Health and Family Welfare, Dept. of ISM and H, 2011.
- 10. Lavekar G.S. et al., *Laboratory guide for the analysis of Ayurveda and Siddha formulations*, CCRAS, Dept. of AYUSH, Ministry of Health and Family welfare, Govt. of India, New Delhi, 2010.

Authors

Praveen M., Post Graduate Scholar, Department of Post Graduate Studies in Rasashastra and Bhaishajyakalpana, K.V.G. Ayurveda Medical College and Hospital, Sullia, Dakshina Kannada (Dist.), Karnataka- 574327.

Harshitha M. Professor, Department of Post Graduate Studies in Rasashastra and Bhaishajyakalpana, K.V.G. Ayurveda

Harshitha M., Professor, Department of Post Graduate Studies in Rasashastra and Bhaishajyakalpana, K.V.G. Ayurveda Medical College and Hospital, Sullia, Dakshina Kannada (Dist.), Karnataka- 574327.

Kottakkal Ayurveda Series: 162



Myopathy - An Ayurvedic Perspective

Dr. M. Abhilash

Price : ₹80/-

Myopathy is mainly a disease involving impairment in dhātu metabolism due to various factors which has been studied in detail. The disease can be congenital or may manifest due to various reasons. The modern science considered the disease as a disorder in the muscle. Studies have been carried out classifying the disease based on aetiology and clinical features.

The thorough knowledge about the pathology has been a guiding line. With respect to āyurveda view of the error in dhātu metabolism, srotorodha, agni and various other causes which has been studied in relation to this disorder. This title gives a discussion on māmsadhatu and a modern evaluation and an āyurveda approach on myopathy.

Āryavaidyan, Vol. XXXII, No. 3, February - April 2019, Pages 20 - 24

Study on Miśreya arka (Hydro distillate of *Anethum graveolens* L.) prepared by three different methods

Shweta Paul, Karunanidhi Sharma, Sanjay Kumar and Parimi Suresh

ABSTRACT: Miśreya is an important drug used in Ayurveda, Unani and Modern system of medicine. In scientific world it is known as Anethum graveolens L., belongs to the family Apiaceae, commonly known as dill, sowa and soya. It is also an ingredient of dill water, which is used in children for abdominal discomfort. Arkakalpana, is an important dosage form in Ayurveda and Unani system of medicine, where water soaked miśreya along with water is placed in distillation apparatus and the distillate is taken as final product. There are different opinions on the ratio of water, drug and distillate in different texts. It is a conflict of interest that which one among these method is the best, present study has been designed to make a conclusion over this. Here three samples has been prepared by following the references of Arkaprakāśaḥ, The Ayurveda Formulary of India and National Formulary of Unani medicine and evaluated on the basis of method, yield and characters of prepared products. It was found that the methods of AFI and NFUM were more convenient, with enough yield and end product of acceptable quality, while the sample by Arkaprakāśaḥ was concentrated, very strong in taste and odour. It can be said that methods of AFI and NFUM can be used for preparing the arka generally.

Key words: Sowa arka, Distillate of soya, Arkakalpana, Arq-e-Soya, Araq-e-Shibbt.

Introduction

Anethum graveolens L. is an important herb that belongs to Apiaceae (Umbelliferae) family. It is also known as miśreya, śatapuspa (in Sanskrit), Shibt, Soya (in Urdu), Sowa, Sava and Soa (Common names) etc. 1 It is used much in Ayurveda and Unani system of medicine. In ayurveda it is indicated in colic pain, indigestion, stomach ache in children and uterine pain.² In Unani medicinal system it is also indicated in abdominal diseases.³ Dill water is used as an ingredient in gripe water, given to relieve colic pain in babies and flatulence in young children.⁴ It is used in various dosage forms like powder, phanta (infusion), taila (oil) and arka (hydro distillate).^{2a} Though main constituent of miśreya is aromatic volatile oil, it can be said that arkakalpana is one of the best option to obtain maximum therapeutic value from it. Arkakalpana can be defined as a liquid preparation obtained by distillation of certain liquids or of drugs soaked in water using arka yantra.⁵ It is

also mentioned in fundamental dosage forms by Rāvaņa in Arkaprakāśaḥ.6 Arka is distilled liquid dosage form and arkayantra which is a classical distillation apparatus. In āyurveda, Arkaprakāśah is a dedicated book to Arkakalpana has mentioned the use of miśreya arka in agnimāndya (impaired digestive fire), yon isula (uterine or vaginal pain) and krmiroga (worm diseases/helminthiasis). 6a While in Unani, Su-e-Hazam (dyspepsia), Qillat-ul-Baul (oliguria), Nafkh-e-Shikam (flatulance).7 Both the systems has described their own method of preparation. Ayurveda Formulary has also described their method for preparation of miśreya arka. So now there are three main method of miśreya arka preparation. So it is the need of the time to evaluate the best method among these, so that the best quality of arka can be obtained to get maximum therapeutic properties. Considering this point in mind, the present study was planned, where miśreya arka was prepared by all these methods and analyzed in laboratory.

Materials and methods

Raw drug: Dried miśreya fruits were procured from Pharmacy, National Institute of Ayurveda, Jaipur. Distilled water was taken from Drug testing laboratory, Department of Rasashastra and Bhaishajyakalpana (RSBK), National Institute of Ayurveda (NIA), Jaipur.

Instruments: Round bottom flask, heating mantle, condenser, receiver flask, rubber tube, stands, clamps, etc.

- Samples of miśreya were analyzed in the Drug testing laboratory, Department of RSBK, NIA, Jaipur.
- The drug was tested for macroscopic, microscopic and physico-chemical parameters and were compared with standards mentioned in The Ayurvedic Pharmacopoeia of India. ^{1a} Table 1.
- After confirmation of authenticity, the miśreya was crushed and made into coarse powder.

Table 1 Showing the physico chemical characters of miśreya							
Sl.No. Physico-chemical parameters API standards Sample (analyzed)							
1.	Foreign matter (Total %)	Not more than 5 %	0.92				
2.	pH (10% aqueous solution)	Not mentioned	6.5				
3.	Total Ash (% w/w)	Not more than 14 %	13.5				
4.	Acid insoluble ash (% w/w)	Not more than 1.5 %	3				
5.	Water soluble extractive (% w/w)	Not less than 15%	18.8				
6.	Alcohol soluble extractive (% w/w)	Not less than 4%	12				
7.	Volatile oil (% v/w)	Not less than 3 %	3%				

- Preparation of arka was done in standard laboratory conditions.
- Three samples of arka were prepared with three different references i.e. Arkaprakāśah, The

Ayurveda formulary of India and National Formulary of Unani medicine where in all these references ratio and quantity of miśreya, water (taken) and arka (distilled) are different as mentioned in Table 2 and 3.

Table 2							
Showing the ratio of water and misreya in different texts							
Reference	Ratio of						
Reference	Miśreya	Water taken	Arka (distilled)				
Arkaprakāśaḥ ^{6b,6c}	1	2	Not mentioned. (Till praśasta arka				
			obtained) ^{6d}				
Ayurveda Formulary of India ⁸	1	7	5				
Unani system of Medicine ^{7a,7b}	1	20	10				

Table 3							
Showing the quantity of water and miśreya according to three texts							
Reference	Quantity of						
Reference	Miśreya	Water taken	Arka (distilled upto)				
Arkaprakāśaḥ	32 gm	64 ml	25 ml				
Ayurveda Formulary of India	50 gm	350 ml	250 ml				
Unani system of medicine	25 gm	500 ml	250 ml				

- Same method of preparation was followed for preparation of samples as per all (three) above mentioned references.
- Coarse powder of miśreya were kept for overnight soaking and half amount of mentioned water in each case was added. On next morning remaining water was added to it and transferred into a round bottom flask. It was placed over heating mantle and distillation apparatus was assembled. Receiver flask was marked upto the amount of arka which was to be extracted. Then heating was started, temperature was gradually increased upto 100°C and kept for 30 minutes and then it was reduced to 50°C and was maintained throughout the procedure till appropriate quantity of arka was obtained. Then the arka was preserved in air tight container and marked as Sample 1 (Arkaprakāśaḥ), Sample 2 (AFI) and Sample 3 (National formulary of Unani medicine).
- After the preparation of arka all the three

- samples were analyzed for organoleptic and physico-chemical characters (i.e. pH, specific gravity and refractive index) in the Drug testing laboratory, Department of RSBK, NIA, Jaipur and the results were recorded.
- All the analytical tests i.e. foreign matter, ^{1b} total ash, ^{1c} acid insoluble ash, ^{1d} water soluble extractive, ^{1e} alcohol soluble extractive, ^{1f} volatile oil, ^{1g} specific gravity, ^{1h} and refractive index ¹ⁱ was carried out by following The Ayurvedic Pharmacopoeial references.

Results

Arka obtained:

Sample 1 (Arkaprakāśaḥ) - 25 ml; Duration: 5 hrs.

Sample 2 (AFI) - 250 ml; Duration: 7 hrs.

Sample 3 (NFUM) - 250 ml; Duration: 7 hrs. 45 min.

Results of analytical tests: See Table 4.

Table No. 4 Results of three samples of Miśreya arka							
Character Sample 1 (A.P.) Sample 2 (AFI) Sample 3 (NFU							
Color	Transparent	Transparent	Transparent				
Odour	Typical miśreya like (Strong)	Typical miśreya like	Typical miśreya like				
Taste	Kaṭu, tikta (Strong)	Kaṭu, tikta	Kaṭu, tikta				
Appearance	Watery (slight turbid)	Clear watery	Clear watery				
Clarity	Floating oil drops	Floating oil drops	Floating oil drops				
pH	6	6.3	6				
Specific gravity	1.002	1.003	1.001				
Refractive index	1.32	1.33	1.35				

Discussion

Arka or *Araq* is an important dosage form in āyurveda, Unani system of medicine and also in Modern system of medicine,^{3a,9} where it is used individually or in combination to improve digestion in children, to cure colic pain, indigestion (mainly) and other disease conditions. It is an aromatic plant and volatile oil is the main constituent. Hima, phāṇṭa,

arka or *araq*, *saiyyalat*, *qutur* and *shrabat* are the dosage forms which were developed by the scholars of Ayurveda and Unani system of medicine for this type of drugs. Among all these arka kalpana is the best due to some reasons like it contains maximum volatile oils, aroma and its transparent color, having almost watery appearance and its taste not very strong. All these things make it much easier to take as a

medicine than all the other options. This high palatability and higher shelf life (6-12 months)^{10,11} or till the presence of praśasta arka properties.^{6e}

Instead of the arkayantra described in classics for the preparation of arka, simple distillation apparatus is used in today's practice and in present study also for preparation, as it is tedious job to prepare with the arkayantra. Simple distillation apparatus is easily available, very easy to assemble, easily controlled (temperature, quality of distillation etc.) and provides sophistication also. Coarse powder was preferred over powder or raw drug as it provides sufficient surface area for extraction of active constituents and also do not get chopped as fine powder. Coarse powder of the drug was soaked in water for overnight, hence, drug becomes soft and arka can be easily extracted out of it. Soaking time of yavāni and miśreya drugs in the water has given astaprahara in sunlight and astaprahara in moonlight¹¹ i.e. 48 hrs. of long duration which may cause over soaking, giving a bad smell to the mixture due to growth of microbes in it. So soaking time was also reduced to 12 hrs. and the mixture was subjected to simple distillation. In Arkaprakāśah, miśreya is mentioned under kathina dravya and so for the preparation of arka of kathina dravya amount of water told is twice of the drug. While preparing on a small scale i.e. in the laboratory level for experimental study, it was found to be quite difficult to distill such small amount of arka as it gets charred and some turbidity is also seen. Initially it was heated for 30 minutes at 100°C and later the temperature was reduced to 50°C. It was maintained throughout the procedure. After boiling, the temperature was maintained at 50°C for evaporation of volatile substance and 35-50 minutes later arka started distilling out. After collection upto a marked amount (as per followed reference), heater was switched off. Odour and taste of the arka was same as miśreya, transparent in color and oil droplets were seen on the surface of the arka. In Arkaprakāśah, agni pramana (amount of heat) and time duration has been

said as parameter for extraction of arka, but the definite amount is not clearly mentioned. Today, it is quite difficult to decide and carry out the distillation according to the agni pramāṇa. Beyond this, various instruments and methods are available which are more convenient and easy to control the heat during the process. Among all the references, method of Unani system of medicine seems better, where water quantity and distilled arka was found sufficient that it can drain maximum volatile oil from the drugs.

Conclusion

After completion of the study it was concluded that maximum yield was obtained by following the method of Unani system. Arka obtained by the method of Arkaprakāśaḥ was concentrated, with strong taste and smell. Methods of AFI and Unani system were found more convenient for the preparation of arka generally, but for concentrated and highest potency, method of Arkaprakāśaḥ is the best. Evaluation of the same through preclinical and clinical studies are suggested on the basis of the present study.

Acknowledgements: Director and Dean, National Institute of Ayurveda, Jaipur. Head of the Department, all the teachers, scholars and team members, Department of Rasashastra and Bhaishajyakalpana, National Institute of Ayurveda, Jaipur, Rajasthan.

References

- 1. *The Ayurvedic Pharmacopeia of India*, Part I, Vol. II, P 153, National Institute of Science Communications and Information Resources, New Delhi, CSIR. 1999.
- 1a. Ibidem., Part I, Vol. II, P 153-4
- 1b. Ibidem., Appendix 2.2.2, Part I, Vol. II, P 190
- 1c. Ibidem., Appendix 2.2.4, Part I, Vol. II, P 190
- 1d. Ibidem., Appendix 2.2.5, Part I, Vol. II, P 190
- 1e. Ibidem., Appendix 2.2.7, Part I, Vol. II, P 191
- 1f. Ibidem., Appendix 2.2.6, Part I, Vol. II, P 191

- 1g. Ibidem., Appendix 2.2.10, Part I, Vol. II, P 191
- 1h. Ibidem., Appendix 3.1.3, Part I, Vol. II, P 208
- 1i. Ibidem., Appendix 3.1.2, Part I, Vol. II, P 207
- 2. Sharma P.V., *Dravyaguna-Vijnana*, Pancam adhyaya, Part II, P 404, Chaukhambha Bharati Academy, Varanasi, 2011.
- 2a. Ibidem., Part II, P 404
- 3. Khare C.P., *Indian herbal remedies*, Rational Western Therapy, Ayurvedic and other traditional usages, Botany, P 60-1, Springer, Berlin, New York, 2004.
- 3a. Ibidem., P 60-1
- 4. Pulliah T., *Medicinal Plants in India*, Vol. 1, P 55-6, Regency Publications, New Delhi, 2002.
- 5. Radharaj D.K., *Sabdakalpadrumam*, 3rd Edition, P 1,8 and 9, Chaukhambha Sanskrit Series, Varanasi, 1967.
- 6. Ravana, *Arkaprakasa*, Commentary in Hindi by Tripathi I., Prathama sataka, P 9, Verse No. 46, 4th Edition, Chowkhamba Krishnadas Academy, Varanasi, 2015.
- 6a. Ibidem., Tritiya sataka, Verse No. 11, P 39
- 6b. Ibidem., Dvitiya sataka, Verse No. 10-12, P 21
- 6c. Ibidem., Tritiya sataka, Verse No. 11, P 39

- 6d. Ibidem., Prathama sataka, Verse No. 74-5, P 14
- 6e. Ibidem., Prathama sataka, Verse No. 74-75, P 14
- 7. Anonymous, 4.9.6 Araq-e-Badiayan, *National Formulary of Unani Medicine*, Part I, P 214, Central Council of Research in Unani Medicine, New Delhi, 2006.
- 7a. Ibidem., 4.9.6 Araq-e-Badiayan, Part I, P 214
- 7b. Ibidem., Appendix 6.III.2 Araqiyat (General Method of Preparation), Part I, P 237.
- 8. Anonymous, *The Ayurvedic Formulary of India*, 2:4 Misreya arka, Part I, P 28, 2nd Edition, National Institute of Science Communications and Information Resources, CSIR, New Delhi, 2003.
- 9. Available from https://www.webmd.com/vitamins/ai/ingredientmono-463/dill. Cited on 21th May, 2019.
- 10. Khan Foroz et.al, Accelerated Stability Study of Arqe Ajwain, *International Journal of Pharmaceutical Sciences Review and Research*, 52(1), Article No. 01, P 1-6, September-October, 2018.
- 11. (8)th point, Rule 161B, Drug and Cosmetic Rules 1945, under The Drugs and Cosmetics act 1940, updated and w.e.f. 12-8-2016.

Authors

Shweta Paul, Consultant, Shree Vishwapranda Ayurvedic Chikitsalya and Panchakarma Centre, Yermala, Kallam, Osmanabad, Maharashtra. Email: shreevishvapranda@gmail.com

Karunanidhi Sharma, Research officer, Multani Pharmaceutical Ltd., New Delhi.

Sanjay Kumar, Associate Professor, Department of Rasashastra and Bhaishajya Kalpana, National Institute of Ayurveda, Jaipur, Rajasthan.

Parimi Suresh, Professor, Department of Rasashastra and Bhaishajya Kalpana, National Institute of Ayurveda, Jaipur, Rajasthan.

Āryavaidyan, Vol. XXXII, No. 3, February - April 2019, Pages 25 - 30

A case study on healing effect of Apāmārga kṣāra (caustic therapy) in śalyajanya nāḍī vraṇa after chedana karma

Rajasree G. and Anita Patel K.

ABSTRACT: A pilonidal sinus or śalyajanya nāḍ̄i vraṇa is a cavity filled with hairs and granulation tissue. There are several methods to treat pilonidal sinus, but the recurrence rate is more due to unhealthy healing of excised wound in post-operative period. According to Suśruta, treatment of śalyajanya nāḍ̄i vraṇa is nirharaṇa of śalya followed by mārgaśodhana and ropaṇa. Here, single case is reported with pre and post study of apāmārga (*Achyranthes aspera* L.) kṣāra application in śalyajanya nāḍ̄i vraṇa after chedana karma, which is assessed based on colour, pain, discharge, granulation tissue and size of wound on every week, till the wound gets completely healed. By this treatment pilonidal sinus got completely healed by 42 days. Study was concluded as single application of apāmārga kṣāra after chedana karma is having good healing effect, as it makes the surgical wound healthy and clean.

Key words: Pilonidal sinus, Śalyajanya nāḍi vraṇa, Pratisāraṇiya kṣāra, Chedana karma

Introduction

A pilonidal sinus (śalyajanya nāḍā vraṇa) is a cavity filled with hairs and granulation tissue. Common site of pilonidal sinus is posteriorly in the midline over sacro-coccygeal area and natal cleft. It is an acquired disease that often takes a chronic course. The incidence of the disease is calculated to be 26 per 100,000 people.¹ Pilonidal disease has a male predominance.² The disease occurs 2.2 times more often in men than women.

Hair broken off by friction due to continuous sitting collect in the cleft and enter into the sweat glands. After the initial entry dermatitis and inflammation start around the loose hair and once the sinus is formed, intermittent negative pressure of the area may suck other loose hair into the pit. It affects inter gluteal furrow. The sinus passes upwards and forwards towards the sacrum. It may possess branching side channels. It occurs in young adults or teenagers.

There are several methods to treat pilonidal sinus like Karydakis procedure, Bascom's technique, Z-plasty, Radical excision, etc. But the recurrence rate is more due to unhealthy healing of excised wound in post-operative period.

In āyurveda there are eight types of nāḍi vraṇa. Among that śalyajanya nāḍi vraṇa or āgantuja nāḍi vraṇa is taken as pilonidal sinus as it is caused by hair. Kṣārasūtra application is widely practised treatment modality in śalyajanya nāḍi vraṇa (pilonidal sinus), but it needs weekly thread changing and it is a painful procedure through out the course of treatment (till the sinus track gets completely cut open). Ācārya Suśruta has explained the treatment of śalyajanya nāḍi vraṇa as nirharaṇa of śalya followed by mārgaśodhana and ropaṇa.³ In the indication of pratisāraṇiya kṣāra, Suśruta has included nāḍi vraṇa. In the indication of chedya vyādhi, asthi-māmsaka śalya is also included.

Hence, an attempt was made to treat pilonidal sinus by nirharaṇa of roma (hair) śalya with the help of chedana karma (excision) which was followed by mārga-śodhana and ropaṇa by application of apāmārga kṣāra.

Method of preparation of apāmārga kṣāra

10 kg of apāmārga (whole plant) was collected and formed into a heap. The whole plant was burnt into ashes, and it was allowed to cool by itself. The whole

ash was collected (1 kg) and mixed with six litres of water and stirred well, allowed to settle overnight. Next day it was filtered through a double folded cloth for 21 times and the residue was thrown out. Obtained amber coloured filtrate was subjected to mandagni (mild fire). When the content was reduced to half; about 1/3rd of kṣārajala (caustic water) was taken out of the vessel. 100 gm of śukti (conch shell) was heated red hot and was then mixed with 1/3rd of ksārajala to dissolve it completely. Thus dissolved śukti was added to the boiling ksārajala and continued to boil. Meanwhile 10 gm of citrakamūla (Plumbago indica L.) kalka was added to the boiling kṣārajala and allowed to boil for a few more minutes. When the content attained consistency as described by Suśruta⁴ (not too liquid nor too solid) it was removed from fire and transferred into a separate container with lid. Figure 1.

Figure 1 Apāmārgakṣāra



Case Report

A 21 year old female patient came to surgery OPD on March 2016 with complaints of pus discharge and pain around the natal cleft since one week. She had a past history of pilonidal abscess and did incision and drainage in 2012 and 2013 from an allopathic hospital. In 2015 December pilonidal sinus appeared and it was treated with incision and drainage. It was healed and they were advised to do excision for the same

from that modern hospital. Due to recurrence the patient was not willing to go for modern treatment.

On examination opening was present at natal cleft (sacral region) with pus discharge. On palpation induration was present with tenderness. The direction of sinus was downwards i.e., towards skin pit. Figure 2. On probing the length of the track was almost 5cm. Figure 3. Blood routine, liver function test, renal function test, lipid profile and blood sugar was in normal limits. HIV, HBsAg and VDRL were negative. ECG was normal.

Figure 2
Pilonidal sinus



Figure 3
Probing the Pilonidal sinus



Procedure planned was chedana karma (excision) followed by single application of apāmārga ksāra.

Pūrva karma (Pre-operative preparation)

Sodium phosphate enema (proctoclysis) was given early in the morning on the day of operation. Injection T.T. (Tetanus toxoid) 0.5 ml IM was given and plain Xylocaine 2% was given intradermal for sensitivity test. Gorocanādi gulika was given as a premedication.

Pradhāna karma (Operative procedure)


Patient was made to lie down in prone position. Painting to the operative site was done with triphalā kaṣāya. Followed with draping. Local anaesthesia was given to the site of pilonidal sinus with Xylocaine 2%. Probing was done to see the length of the tract. With the help of scalpel (blade no.11 and B.P handle no. 3) an elliptical incision was made around the pilonidal sinus. The whole sinus tract was excised deep up to the presacral fascia. Figure 4.

Figure 4
Doing excision around the Pilonidal sinus track



During the whole surgical process hemostasis was maintained by giving pressure with surgical mop. After the above chedana karma pratisāraṇīya kṣāra prepared from the apāmārga was applied. Figure 5. After application of the kṣāra, it was kept for 100 mātrā kāla (1 minute) and it was washed with jambīra

Figure 5
Application of Apāmārga ksāra



[Citrus limon (L.) Osbeck] svarasa to operative wound. Figure 6. Hence, neutralization occured by alkaline and acid reaction.

Figure 6
Washing with Jambira svarasa



Pascāt karma (Post-operative procedure)

In the post-operative wound, chemical cauterization occurred and bleeding was arrested. Figure 7. Daily cleaning and dressing was done with normal saline till the wound gets completely healed. Weekly shaving was done around the operative wound. The wound was assessed weekly till it got completely healed.

Figure 7
Post operative wound on surgical day



Results and Discussion

Results are given in Figures 8, 9, 10, 11 and 12 and Table 1.

Figure 8
Post-operative wound on 7th day



 $Figure \, 9 \\$ Post-operative wound on 14^{th} day



28

Figure 10
Post-operative wound on 21st day



 $Figure \ 11$ Post-operative wound on $28^{th} \ day$



 $Figure \ 12$ Post-operative wound on 35^{th} day



 $Figure \ 10$ Post-operative wound on $42^{nd} \ day$




Table 1 Changes observed during the course of treatment							
Days 7 14 21 28 35 42							
Colour of wound	Red	Red	Red	Red	Red	Healed	
Pain	Absent	Absent	Absent	Absent	Absent	Absent	
Discharge	Pale	Absent	Absent	Absent	Absent	Absent	
Size(cm ²)	11.5	11.5	8	4	1.5	0	
Granulation tissue	Healthy	Healthy	Healthy	Healthy	Healthy	Healed	

- Pain was present only for 1st two days after surgery and it was relieved by use of analgesics.
- The excised wound was completely healed within 42 days.
- Application of apāmārga kṣāra after excision of pilonidal sinus helped in scraping of pits in the surrounding tissue of the sinus.
- Apāmārga kṣāra acted as chemical cauterization. Immediately after chedana karma the bleeding was arrested and it had raktasthambhana property.
- pH value of apāmārga kṣāra was 11.1
- According to Arrhenius theory, the acids are substances which produce hydrogen ions and base produces hydroxide ions. Hence, neutralization occurs by hydrogen ions and hydroxide ions reaction and produce water. Hence, pratisāraṇīya kṣāra was washed with jambīra svarasa neutralises it.

$$H^+ + OH^- = H_2^-$$

- It has anti-inflammatory and antibacterial property.
- It avoided the formation of unhealthy granulation tissue and the wound got healed from the base.
- Healing was more seen in breadth wise rather than length wise healing.
- It performs chedana, bhedana and lekhana properties among the astavidha śastra karma.⁵

• Since three years there is no reccurence of the disease.

Conclusion

- Application of apāmārga kṣāra in pilonidal sinus after excision helped to heal the wound within 42days.
- Post-operative pain was very less compared to other treatment modalities.
- Minimum hospitalisation is required.
- Bleeding was absent.
- There is no scope for reccurence since all pits adjecent to sinus track are scrapped.

Acknowledgements

Sri Chandrasekharendra Saraswathi Viswa Mahavidyalaya University, Kanchipuram, Dr. Abdul shukkoor, Professor and Head, Department of Salyatanta, Govt. Ayurveda College, Tripunithura and Dr. Benedict P., Associate Professor, Govt. Ayurveda College, Thiruvananthapuram, for giving guidance and support.

References

- 1. Sondenaa K., Nesvik I., Andreson E., Natas O. and Soreide J.A., Patient Characteristics and Symptoms in Chronic Pilonidal Sinus Disease, *International Journal of Colorectal Disease*, 10:39-42, Springer, 1995.
- 2. Bailey and Love's *Short Practice of Surgery*, Edited by Russell R.C.G., Norman Williams S., Christopher. J.K, and Bulstrode, Chapter 72, The Anus and Anal Canal, P1249, 24th Edition, Hodder Education, Great Britain, 2004.


- 3. Susruta, *Susrutasamhita*, with Nibandhasangraha commentary of Dalhana and Nyayachandrika Panjika of Gayadasa on Nidanasthanam, Edited by Vaidya Jadavji Trikamji Acarya, Cikitsasthanam Chapter 17, Visarpa-nadisthana roga ciktsa adhyayam, P 468, Chowkhambha Krishnadas Academy, Varanasi, 2008.
- 4. Rajasree G., *Anorectal Disorders Ayurvedic Approach*, Chapter 4, P 35, 1st Edition, Chaukhambha Orientalia, Varanasi, 2015.
- 5. Susruta, *Susrutasamhita*, Edited by Kaviraj Kunjalal Bhishagratna, Chapter11,Vol. 1, Ksharapakavidhi adhyaya, P 75, 2nd Edition, Chowkhambha Sanskrit Series Office, Varanasi, 2002.

Authors

Rajasree G., Assistant Professor, Department of Salyatantra, Govt. Ayurveda College, Tripunithura, Kerala.

Anita Patel K., Associate Professor, Department of Salyatantra, Sri Jayendra Saraswathi Ayurveda College, Chennai, Tamil Nadu.

Kottakkal Ayurveda Series: 166



The theoretic frame work of srotorodham and its clinical applications

Dr. Praveen Balakrishnan

Price : ₹ 100/-

The word srotas denotes 'space for moving' and rodha meaning 'obstruction' to the functions of $v\bar{a}yu$. This volume gives the basics of srotas and srotorodha and the treatment principles of srotorodha.

Āryavaidyan, Vol. XXXII, No. 3, February - April 2019, Pages 31 - 39

Management of jalodara *vis-a-vis* ascites with special reference to Jalodarāri rasa as virecana yoga

Sanjay Kumar Giri and Sanghamitra Patnaik

ABSTRACT: Jalodara is a clinical condition described in ayurveda that closely resembles with the clinical features of ascites. Elimination of both fluids and morbid factors through virecana (therapeutic purgation) is the first line of treatment in the management of jalodara in ayurveda, whereas, standard diuretic therapy is the first line therapy for ascitis as per modern medicine. A single blind clinical study was conducted at Department of Post graduate studies in Kayachikitsa, Gopabandhu Ayurveda Mahavidyalaya, Puri, Orissa, to evaluate the efficacy of Jalodarāri rasa, a virecana yoga mentioned in āyurveda classics, in patients suffering from jalodara and to compare the ayurveda line of treatment with that of modern medicine. Thirty patients aged between 29-63 years were divided into 20 patients in trial group and 10 patients in control group. The patients in the trial group were prescribed with Jalodarāri rasa, cow's milk and lājāmanda (a preparation made from puffed rice) and those in the control group were prescribed a diuretic Lasilactone (20mg Furosemide and 50mg Spironolactone). The assessment was based on the changes in the clinical signs and symptoms. In the trial group 5%, 50%, 30% and 15% patients experienced maximum, moderate, mild and no improvement whereas, in the control group it was 0%, 30%, 40% and 30% respectively. It was observed that patients in both groups experienced comparable changes after treatment but the patients in the trial group experienced additional benefits in terms of general debility (p<0.001) and fluctuant abdomen (p<0.001). Thus it was found that Jalodarāri rasa is a very potent virecana yoga that can pursue out the morbidity associated with Jalodara. This study also proved that ayurveda treatment is equally effective as modern diuretic therapy in the treatment of jalodara or ascitis.

Key words: Ascitis, Diuretics, Jalodara, Pañcakarma, Virecana

Introduction

Jalodara, a condition described in ayurveda, characterized in udara guha is accompanied by symptoms such as anorexia, heavy distended abdomen, tastelessness of mouth, scanty urination and hard faeces.^{1, 2} It is mainly caused by the intake of cold water after samsodhana, loss of digestive fire, etc. ^{2a,3} It is analogous to ascites in the modern parlance where accumulation of several litres of serous fluids in peritoneal cavity is found. ⁴ Ascites is secondary to hepatic diseases, renal diseases, malignancies, cardiac failures, tuberculosis, malnutrition and so on. Jalodara has been described as a terminal condition of udararoga in ayurveda. In malnutrition the collection of intra-peritonial fluid occurs due to hypoproteinemia.⁵ In view of hypoproteinemia elimination by purgation of both fluid and morbid factors is the foremost aim in the management of ascites. Virecana, one among the pañcakarma, is considered as the prime line of treatment in jalodara.⁶ Considering this fact Jalodarāri rasa, a virecana yoga referred in Bhaiṣajyaratnāvali was selected for the clinical trial under the Department of Post graduate studies in Kayachikitsa, Gopabandhu Ayurveda Mahavidyalaya, Puri, Orissa.⁷

Jalodarāri rasa, commonly used in practice in the treatment of jalodara especially in this part of the country gives satisfactory result. Hence, this study was designed to establish the efficacy of this classical virecana yoga by using scientific parameters with statistical analysis.

Further, there is no much documentation on the comparative evaluation of virecana in āyurveda to

that of diuretic therapy in modern science. Hence, the present study was conducted.

Materials and methods

Source of study: OPD and IPD of Gopabandhu Ayurveda Mahavidyalaya, Puri, Orissa.

Design of the study

Number of patients (sample size): Trial group (T_1) - 20 and Control group (T_2) - 10.

Duration of study: 30 consecutive days for both trial and control group patients.

Name of the trial drug with ingredients: Jalodarāri rasa contains haridrā, pippalī, maricaḥ, tāmra bhasma and purified jepāļaḥ.

Bhāvana dravya: Snuhīkṣīra: Quantity sufficient

Statistical design

T₁: B.T. Vs A.T. - effectiveness of Jalodarāri rasa was assessed.

T₂: B.T. Vs A.T. - effectiveness of Lass lactone was assessed.

Name of the control drug with composition: Lassilactone- Frusemide - 20mg, Spironolactone - 50mg

Dose of trial drug with vehicle and control drug: Dose of trial drug - 250 mg twicw daily with cow milk,

Dose of control drug- 2 tab twicw daily.

Type of study: Single blind study

Objectives of the study: To assess the clinical efficacy of both trial and control drug and to compare the efficacy of both.

Diet and regimen: Patients were advised to remain on a diet of cow milk alone with lajāmaṇḍa. They were not allowed for normal bath except sponging.

Procurement of the drug: The raw materials were procured from authentic sources. Medicine was

prepared in the rasaśāla of Gopabandhu Ayurveda Mahavidyalaya, Puri, Orissa.

Follow up: After the completion of trial, follow up was made after one month.

Criteria for the selection of cases

Inclusion criteria: On the basis of cardinal features of hypo-protienemia due to malnutrition i.e., enlarged and fluctuated abdomen, increased body weight, general debility and retention of urine and stool, the patients were screened before including for trial.

Patients of age group 29-63 years and both sex were included.

In multiple phases of the study subjects were allocated by random sampling.

Exclusion criteria: Nephro-pathology, tubercular peritonitis, malignancy, cardiac failure, liver cirrhosis, diabetes mellitus and haemorrhagic diseases were excluded.

Clinical parameters for assessment: Patients were screened based on the proforma accepted by the Department of Post graduate studies in Kayachikitsa, Gopabandhu Ayurveada Mahavidyalaya, Puri, Orissa.

Assessment criteria

Subjective

i. Fluctuated abdomen. ii. General debility

Objective

- i. Enlargement of abdomen (abdominal girth)
- ii. Suppression of urine (frequency/24 hours)
- iii. Retention of bowel (frequency/24 hours)
- iv. Urine output (volume/24hrs)
- v. Passage of stool (quantity/24hrs)
- vi. Body weight (to evaluate swelling)

Method of preparation of Jalodarāri rasa: 7

Ingredients: Haridrā: 125 mg, pippalī: 125 mg, maricaḥ: 125 mg, tāmra bhasma: 31.25 mg, śodhita jepāļa: 500 mg, bhāvana dravya (snuhīkṣīra) - Quantity sufficient. Table 1.

Table 1 Rasapañcaka and chemical composition of the ingredients of Jalodarāri rasa							
Drug name	Rasa	Guṇa	Vīrya	Vipāka	Indication	Therapeutic action	Chemical composition
Haridrā (Curcuma longa L.)	Tikta, kaṭu	Rūkṣa laghu	Uṣṇa	Kaṭu	Kapha vāta śāmaka Pitta recaka Pitta śāmaka	Śotha, yakṛt- pḷiha roga	Curcumin, volatile oils
Pippalī (Piper longum L.)	Kaṭu, madhura	Laghu snigda tikṣṇa	Anuṣṇa- śīta	Madhura	Kapha vāta śāmaka	Agni māndya, vibandha, śūla	Volatile oils, piperin, piperidine piplartine
Maricaḥ (<i>Piper nigrum</i> L.)	Kaṭu	Laghu rūkṣa tikṣṇa	Uṣṇa	Kaṭu	Kapha vātahara	Aruci agnimāndya, śūla	Volatile oils, piperin, piperidine piplartine
Tāmra bhasma (Cuprum)	Madhura amļa, kaṭu tikta, kaṣāya	Snigda sara laghu	Uṣṇa- śīta	Madhura	Kapha pitta śāmaka	Pāṇḍu, yakṛt- pḷɨha roga, grahaṇi	CuSO4, CuS, Cu2O, CuO and Cu metal
Jepāļaḥ (Croton tiglium L.)	Kaṭu	Guru, tīkṣṇa	Uṣṇa	Kaṭu	Vāta kaphahara	Śopha, jalodara	Steamic, palmitic, tiglic, oleum crotonis
Snuhī kṣīra (Euphorbia neriifolia L.)	Kaṭu	Snigda laghu	Uṣṇa	Kaṭu	Vātahara	Gulma, udara ādhmāna	Euphorbon, Starch

All the kāṣṭauṣadhī (herbal ingredients) were made into fine powder. Tāmara bhasma was added in khalva yantra, then soaked in snuhī kṣīra (qs) and was given mardana (trituration). This process was continued for one day and snuhī kṣīra was added accordingly to the need. Then vaṭi (tablet) weighing 2 ratti (250mg) mātra was prepared and allowed to dry. After drying it was preserved in a tight container.

Assessment scale

Enlargement of abdomen (abdominal girth)

Grade 0: (No improvement) proportionate with body parts.

Grade 1: (Mild improvement) 2-4 cms.

Grade 2: (Moderate improvement) 5-8 cms.

Grade 3: (Maximum improvement) above 8 cms.

Fluctuated abdomen

Grade 0: Soft, not fluctuant

Grade 1: (Mild), soft, fluctuation changes with change of posture

Grade 2: (Moderate), soft, fluctuation not changes with change of posture.

Grade 3: (Severe), dull, fluctuation not change with change of posture.

Suppression of urine (in frequency/24hrs)

Grade 0: 6 times/day with proper quantity

Grade 1: (Mild) > 3 times/day, Scanty

Grade 2: (Moderate) 2-3 times/day, Scanty

Grade 3: (Severe), 1-2 times/day, Scanty

Retention of bowel and flatus (frequency/24hrs)

Grade 0: Defection 2 times/day with satisfaction and flatus passed regularly.

Grade 1: (Mild), defectaion < 2times/day with satisfaction having flatus passed.

Grade 2: (Moderate), defectaion < 1-2times/day, having flatus passed occasionally.

Grade 3: (Severe), defectaion restricted to once per day or less having flatus not passed.

Urine output (in ml/24hrs)

Grade 0: (Normal) around 1500ml/day

Grade 1: (Mild), >551ml/day - <1500ml/day with turbidity

Grade 2: (Moderate), >451ml/day - <550ml/day with turbidity

Grade 3: (Severe), <450ml/day with turbidity

Passage of stool (in gms/24hrs)

Grade 0: > 200 gm/day

Grade 1: (Mild), 101-200gm/day Grade 2: (Moderate), 51-100 gm/day

Grade 3: (Severe), 0-50 gm/day

Body weight reduction in kg

Grade 1: 1-2 kg (Mild improvement)

Grade 2: 2-3 kg (Moderate improvement)

Grade 3: above 3 kg (Maximum improvement)

General debility

Grade 0: (Normal)

Grade 1: Debilitated, having normal decubitus

Grade 2: Debilitated upto the extent of inability to perform the normal decubitus with help.

Grade 3: Debilitated up to the extent of inability to perform the normal decubitus not even with assistance.

Assessment scale and score

The grade points were seen to assess the severity of different signs and symptoms. Table 2.

Table 2 Assessment scale and score						
Sl.No. Sign Severity Grade Grade poi (score)						
1.	+++	Severe	G 3	3		
2.	++	Moderate	G 2	2		
3.	+	Mild	G 1	1		
4.	-	Normal	G 0	0		

Clinical assessment of results

- 1. Maximum improvement: Improvement in all signs and symptoms more than 50% to 75%.
- 2. Moderate improvement: Improvement upto 25% to 50%.

- 3. Mild improvement: Improvement upto 25%.
- 4. No Improvement: Not observed or < 25%.

Statistical analysis


For statistical analysis the mean SD value before treatment of each sign and symptom was compared with mean SD value after 15 to 30 days of treatment. Paired 't' test was used to attain the test of significance. The p < 0.05 was set for significance.

Observations and results

In this study it was observed that in both trial and control group all the patients were having the objective and subjective signs and symptoms.

This study showed that out of 30 patients, 19 (63.33%) patients had history of udararoga where as 11 (36.675%) patients did not have the history of udararoga. Figure 1.

Figure 1
Past history of Udararoga



It was observed that out of 30 patients, 11 (37%) patients were having addiction to tea and coffee, followed by 8 (27%) patients using betel leaf and smoking, 5 (17%) patients using tobacco, 3 (10%) patients each having addiction towards alcohol and bhanga. Figure 2.

Statistical analysis showing the effectiveness of the trial drug and control drug to different signs/symptoms after 15 and 30 days are given in Table 3 and 4 respectively.

Aryavaidyan Aryavaidyan

Tobacco

Alcohol

Bhanga

Tea and coffee

10% 16% 10% Betel & Smoking

27%

Figure 2 Incidence of addictions

Table 3
Statistical analysis showing the effectiveness of the trial drug to different sign/symptoms after 15 and 30 days ²

37%

316	Statistical analysis showing the effectiveness of the trial drug to different sign/symptoms after 15 and 50 days						
Sl. No.	Signs/ symptoms	Before treatment	After (15 days) treatment	After (30 days) treatment	t-value	p-value	
1.	Enlargement of abdomen (Abdominal girth)	78.65 <u>+</u> 7.9	74.1±8.08	70.8 ± 9.15	8.73 8.79	<0.001 <0.001	
2.	Fluctuated abdomen	2.15±0.72	1.95 <u>±</u> 0.74	1.45 <u>±</u> 0.74	2.23 5.43	<0.05 <0.001	
3.	Suppression of urine (Frequency in number/24hours)	2.1±0.9	2.0±0.8	2.0±0.8	0.58 0.58	>0.05 >0.05	
4.	Retention of bowel and flatus (Frequency in number/24hours)	1.1±0.8	2.75±1.08	2.05±0.86	8.48 5.68	<0.001 <0.001	
5.	Urine output	445 <u>+</u> 126.4	448.0±125.0	445.5 <u>±</u> 125.5	0.89 0.78	>0.05 >0.05	
6.	Passage of stool	50.9±27.3	350.5±30	298.6 <u>+</u> 32	9.8 8.7	<0.001 <0.001	
7.	Body weight	50.9±2.47	49.7 <u>±</u> 2.55	49.0 <u>±</u> 2.5	8.9 8.0	<0.001 <0.001	
8.	General debility	2.05±0.7	1.75 <u>±</u> 0.6	1.45±0.7	2.85 5.36	<0.05 <0.001	


<0.05: Significant; <0.001: Highly significant

Trial drug is significantly effective to reduce enlargement of abdomen and fluctuated abdomen, to increase bowel and also to increase the passage of bowels, to decrease the body weight and to reduce the general debility. But trial drug (T .D) showed non- significant result in urine output and suppression of urine.

	Table 4								
Sta	Statistical analysis showing the effectiveness of the control drug to different sign/symptoms after 15 and 30 days ²								
Sl.No.	Signs/ symptoms	Before treatment	After (15 days) treatment	After (30 days) treatment	t-value	p-value			
1.	Enlargement of abdomen (Abdominal girth)	77.65 8.36	74.1 8.08	71.8 9.73	5.12 4.6	<0.001 <0.01			
2.	Fluctuated abdomen	2.00 0.77	1.9 0.80	1.60 0.91	0.98 1.98	>0.05 >0.05			
3.	Suppression of urine (Frequency in number/24hours)	1.2 0.4	2.0 0.8	2.0 0.8	9.03` 0.58	<0.001 <0.001			
4.	Retention of bowel and flatus (Frequency in number/24hours)	1.5 0.5	1.5 0.5	2.05 0.86		(the control drug has no action)			
5.	Urine output	315.0 100.12	860.0 73.5	690.0 152.9	11.59 9.8	<0.001 <0.001			
6.	Passage of stool	58 10.5	58.5 11.0	57.9 10.9	0.98 0.78	<0.001 <0.001			
7.	Body weight	50.3 1.95	48.8 2.99	48.9 1.97	6.72 6.41	<0.001 <0.001			
8.	General debility	1.9 0.83	1.9 0.83	1.6 0.9	 1.79	(drug do not effect insigni- ficant) < 0.05			

Control drug is significantly effective to reduce the enlargement of abdomen and decreased fluctuated abdomen. It is significantly effective to increase the frequency of urine as well as urine output and passage of stool and to reduce the body weight. But in case of general debility the control drug is not significantly effective.

Figure 3
Clinical assessment of results after 15 days of treatment in trial and control group



Clinical assessment of results at 15 days and 30 days of follow up: The clinical assessment of the result showed that among trial group, after 15 days of treatment, out of 20 patients 3 (15%) patients got moderate improvement, 13 (65%) patients had mild improvement and the rest 4 (20%) patients could not get any improvement. Among the control group, out of 10 patients 8 (80%) patients got mild improvement but another 2 (20%) patients did not have any such improvement. After 30 days of treatment, in the trial group, out of 20 patients, 1 (5%) patient got

maximum improvement, 10 (50%) patients got moderate improvement, 6 (30%) patients got mild improvement, but the rest 3 (15%) patients could not get any improvement. In the control group, out of 10 patients, 3 (30%) patients got moderate improvement, 5 (50%) patients got mild improvement but the rest 2 (20%) patients could not get any improvement. Figure 3 and 4.

The percentage of improvement in different signs and symptoms are given in Table 5 and Figure 5.

Trial group
Control group


10

Maximum improvement improvement improvement improvement improvement improvement improvement

Figure 4
Clinical assessment of results after 30 days of treatment in trial and control group

	Table 5 The percentage improvement of different signs and symptoms are given below								
Sl.	Groups and		Signs and symptoms						
No.	duration of	Reduction	Reduction	Increase	Increase	Reduction	Reduction	Increase	Increase
	treatment	in abdominal	in fluctuant	in urine	in frequency	in body	in general	in urine	in passage
		girth	abdomen	frequency	of bowel	weight	debility	output	of stool
					movements				
1.	Trial group (in 15 days)	5.78%	12.62%	0%	15%	2.36%	14.63%	0%	350%
2.	Control group (in 15 days)	4.37%	10.68%	158.3%	0%	2.98%	0%	173%	0%
3.	Trial group (in 30 days)	9.98%	22.5%	0%	86.36%	3.73%	29.27%	0%	315%
4.	Control group (in 30 days)	7.93%	20.5%	83.3%	0%	2.78%	0%	153%	0%

Figure 5
Percentage of improvement of different signs and symptoms



Discussion

Jalodara is a clinical entity that demonstrate by increase in abdominal girth and dullness of abdomen caused due to accumulation of fluid in the abdomen.⁸

Svedavaha and udakavaha srotas as well as prāṇa and apāna vāta are predominantly affected in jalodara. Pathological changes occur due to the obstruction in the transport of the fluid in the body were analogous

to ascites based on the patient presentation. Several authorities in \bar{a} yurveda have accepted śodhana cikitsa particularly virecana, to eliminate the obstruction in jalodara.

Discussion on trial drug formulation^{9,10}: Jalodarāri rasa, the trial drug, was formulated with the following ingredients and the mode of action of each drug is explained henceforth. Pippalī and maricaḥ enhance the agni. Jepāļaḥ is an irritant purgative. Tāmra bhasma is having kaphanāśaka and śothahara properties. Haridrā is anti-infective as well as anti-inflammatory in nature. Thus, the depletion in symptoms with jalodarāri rasa as the virecana yoga, is justified.

Discussion on observation: Highest incidence being observed within the age group 29-35 with lower socioeconomic status, which indicates the impact of poverty contributing to malnutrition. The people of ānūpadeśa (habitat), laborers and housewives (occupation) were more reflecting irregular diet and regimen. Most of the patients were having agnimāndya and koṣṭhakāṭhinya. According to the intensity of symptoms maximum dominating signs

and symptoms were protuberant abdomen, everted umbilicus, enlarged blood vessels, shifting dullness as well as fluid thrill and general debility. According to the overall percentage of result in trial group, 5% showed maximum improvement whereas in control group it was 0%, moderate improvement of 50% was found in trial group and it was 30% in control group, mild improvement was 30% in trial group and 40% in control group and no improvement observed was 15% in trial group and it was 30% in control group. In view of this comparison in response, the trial drug is more complimentary than the control drug specifically in general debility and fluctuated abdomen.

So the principle of treatment mentioned against jalodara may also be comprehended by Jalodarari rasa and it can be considered as a highly potent formulation. It is fit to purge out the morbidity associated to jalodara. The response derived by the drug is complimentary to declare and accept the drug as a suitable formulation for the treatment of jalodara.

Below flow chart is showing the mode of action of virecana in jalodara.

Uṣṇa, tīkṣṇa, sūkṣma, vyavāyi ⇒ Vīrya of drug reaches hṛdaya ⇒ Circulate in dhamani, sthūla and aṇu srotas ⇒ Uṣṇa guṇa (viṣyandana), Tīkṣṇa guṇa (chedana) ⇒ Doṣa pracalana and bahirgamana from koṣṭha ⇒ Pṛthvī and jala mahābhūta bhuyiṣṭha ⇒ Adhobhāga prabhāva ⇒ Gudamārga doṣa haraṇa

Conclusion

The results were carefully assessed considering the cardinal signs and symptoms along with statistical adjudication. Assessment of patients treated with Jalodarāri rasa for 15 days and 30 days revealed that there was 50% (moderate improvement), 30% (mild improvement) 5% showed maximum improvement and 15% showed no improvement. Whereas, patients treated with furosemide demonstrated that there was 40% (mild improvement), 30% (moderate improvement) maximum improvement was not observed and 30% not showed any improvement.

Overall comparison showed that Jalodarāri rasa has brought additional benefits when compared to the patients who received only furosemide therapy. In jalodara, udaka-svedavaha srotas as well as apāna-prāṇa vāta are mainly affected which can be well rectified using the aforementioned Jalodarāri rasa. This shows its effectiveness in the management of jalodara or ascites.

Acknowledgements: We are thankful to Dr. N. Panda and Dr. N. C. Das, Former Professors, Department of Post Graduate studies in Kayachikitsa, Gopabandhu Ayurveda

Mahavidyalaya, Puri, Odisha, for guidelines and referring patients for the study, Prof. Vaidya K. S. Dhiman, Director General, CCRAS, New Delhi, for encouraging in scientific publication and Dr. D. Sudhakar, Asst. Director-in-charge, Regional Ayurveda Research Institute for Lifestyle Related Disorders, for providing support in technical aspects of the scientific paper.

References


- 1. Agnivesa, *Carakasamhita*, Vidyodini tika, Edited by Shastry S. N., Cikitsasthanam 13/47, Chowkhambha Bharati Academy, Varanasi, 1989.
- 2. Susruta, *Susrutasamhita*, Ayurveda tatva sandipika, Edited by Ambikadatta Sastry, Nidanasthanam 8/23-34, Chowkhambha Sanskrit Samsthana, Varanasi, 1979.
- 2a. Ibidem., Nidanasthanam 7/5
- 3. Vrddha Vagbhata, *Ashtangasangraha*, Hindi Commentary by Gupta A D., Satyabhama Bai and Pandurang, Nidanasthanam 12/42, Nirnaya Sagar Press, Mumbai.

- 4. Tortora G. J., *Principles of Anatomy and Physiology*, P 585, Harper and Row Publishers, New York, 1981.
- 5. Dey N. C., *The Text Book of Pathology*, P 243, 452 and 473, Dr. Sundari Mohan Avenue, Calcutta, 1978.
- 6. Vagbhata, *Ashtangahrdayam*, Vidyodini tika, Edited by Indradev Gupta, Cikitsasthanam 15/1, Choukhambha Sanskrit Samsthana, Varanasi, 1982.
- 7. Govinda Das Bhishagratna, *Bhaishajya ratnavali*, Commented upon by Kavirajasri Ambika Datta Sashtri and Sri Rajeswara Datta Sastri, Udararogacikitsa 40/77-78, P 536, 14th Edition, Choukhambha Sanskrit Samsthana, Varanasi, 2001.
- 8. Bhavamisra, *Bhavaprakasa*, Hindi Commentary, Edited by Pandey G. S., Cikitsasthanam 41/27-28, Chowkhambha Vidya Bhavan, Varanasi, 1960.
- 9. Shetter N.S., *Jalodara and its management*, Govt. College of Indian Medicine, Mysore, 1983.
- 10. Tripathy G.N., *Jalodara chikitsa me Tamra prapati ki karmukta*, National Institute of Ayurveda, Jaipur, 1987.

Authors

Sanjay Kumar Giri, Research Officer (Scientist-3), Regional Ayurveda Research Institute for Lifestyle Related Disorders (CCRAS), Poojappura, Thiruvananthapuram -12, Kerala. Email: giridr@yahoo.co.in
Sanghamitra Patnaik, Professor, Department of Panchakarma, Sushrutha Ayurvedic Medical College, S-Vyasa, Prasanthi kutira, Jigani, Bangalore, Karnataka.

Kottakkal Ayurveda Series: 144



Relevance of purificatory treatment in degenerative diseases

Dr. G. Purushothamacharyalu and Dr. (Mrs.) G. Arundhathi Purushotham

Price: ₹ 160/-

The diseases which are related to or caused by the process of degeneration are termed as degenerative diseases; it is regarded as a form of cellular injury. Degenerations are named according to the

morphologic change or the nature of the abnormality accumulated material i.e. cellular swelling (cloudy swelling), hydropic, etc. The process of degeneration is regarded as a physiological phenomenon in old age. However, people in younger age also afflicted with the process and suffer from various types of degenerative diseases. This title discusses the relevance of purificatory treatments i.e. śodhana or pañcakarmacikitsa as the most important mode of therapeutic measure in degenerative diseases.

Comparative X-ray fluorescence analysis of Kāsīsa purified by different methods

Manali Anil Visaria and Sheela Pargunde

ABSTRACT: In Rasaśāstra, śodhana is a procedure by which a dhātu or a substance is purified to remove mala or impurities from it. Only after śodhana, dhātu can be subjected to māraṇa (incineration) thereby making it efficient for consumption by human beings. Kāsīsa is classified under the uparasa in Rasaśāstra. Various grantha (ancient texts) have mentioned kāsīsa śodhana by different methods with different dravya like bhṛṅgarāja svarasa, kāsamarda rasa, pañca pitta, rājakośātaki, etc. This study was aimed to compare XRF analysis of kāsīsa purified by different methods. Aśuddha kāsīsa was purified as per the reference mentioned in Rasataraṅgiṇi, Rasaratnasamuccaya and Rasārṇava. XRF analysis of aśuddha kāsīsa and śuddha kāsīsa was done. The results of XRF analysis showed that aśuddha kāsīsa (Iron-71.8%, Sulphur-25%), śuddha kāsīsa done by svedana in dolāyantra with bhṛṅgarāja svarasa (Iron-74.58%, Sulphur-16.57%), śuddha kāsīsa done by svedana in dolāyantra with bhṛṅgarāja kvāthaḥ (Iron-69.2%, Sulphur-17.9), śuddha kāsīsa done by dissolving in bhṛṅgarāja svarasa (Iron-76.46%, Sulphur-20.75%), śuddha kāsīsa done by bhāvana with kāsamarda kvāthaḥ (Iron-70.7%, Sulphur-18.3%). Among all the methods of śodhana, percentage of iron and sulphur were found more in śuddha kāsīsa done by the method of dissolving in bhṛṅgarāja svarasa.

Key words: Kasis, XRF analysis, Iron, Sulphur

Introduction

Sodhana is defined as a procedure in which a dhātu or a substance is purified by pesana, svedana, etc. to remove mala from it.1 Sodhana is an important concept explained in Rasaśāstra for preparing any medication especially the oral medications. Hence, śodhana is considered as an initial procedure of preparation of any medication. Kāsīsa is one such metal described in Rasaśāstra under uparasa varga. Sodhana of kāsīsa is mentioned in various grantha of āyurveda. It can be purified by various dravya such as bhrngarāja [Eclipta alba (L.) Hassk.] svarasa as mentioned in Rasatarangini and Rasaratnasamuccaya, kāsamarda rasa, pañca pitta and rājakośātaki as mentioned in Rasārņava, etc. After the śodhana of kās isa, its elemental composition can be derived from XRF (X-ray fluorescence) analysis. XRF can be defined as an emission of characteristic X-ray from a material that has been excited by bombarding with high-energy X-rays or gamma rays.2

Aim of the study

To compare XRF analysis of kāsīsa purified by different methods.

Objective of the study

Determination of elemental composition of śuddha kāsīsa by XRF analysis.

Materials and methods

Śodhana of aśuddha kāsīsa was done as per the reference mentioned in Rasataraṅgiṇi, Rasaratnasamuccaya and Rasārṇava.

a) First and second methods of purification was done as per the references mentioned in Rasatarangini. First method of purification was done by subjecting aśuddha kāsīsa to svedana in doļāyantra with bhṛṅgarāja svarasa for three ghaṭika. Figure 1.

Second method of purification was done by svedana in dolāyantra with bhṛṅgarāja kvāthaḥ for three ghaṭika.³ Figure 2.

1. Preparation of Pottali

2. Svedana

3. Drying of śuddha kāsīsa

Figure 1 Svedana in Doļāyantra with Bhṛṅgarāja svarasa

Figure 2 Svedana in Doļāyantra with Bhṛṅgarāja kvāthaḥ



b) Third method of purification was done as per the reference mentioned in Rasaratnasamuccaya. It was done by dissolving aśuddha kāsīsa in bhṛṅgarāja svarasa and it was kept to dry in sunlight.⁴ Figure 3.

c) Fourth method of purification was done as per the reference mentioned in Rasārṇava. It was done by giving three bhāvana(trituration) of kāsamarda (*Cassia occidentalis* L.) svarasa.⁵ Figure 4.

Figure 3 Dissolving Aśuddha Kāsīsa in Bhṛṅgarāja svarasa



Figure 4 Bhāvana in Kāsamarda svarasa



XRF analysis of aśuddha k $\bar{a}s\bar{i}sa$ and śuddha k $\bar{a}s\bar{i}sa$ were done.

Result

The following tables (Table 1, 2 and 3) are showing

the quantity of $k\bar{a}s\bar{i}sa$ before and after śodhana; XRF analysis: Composition of oxide- (Unit- mass %) and XRF analysis: Composition of element- (Unit- mass %) respectively.

Table 1 Quantity of Kāsīsa before and after śodhana						
Kāsīsa	Svedana in doļāyantra with bhṛṅgarāja svarasa	Svedana in doļāyantra with bhṛṅgarāja kvātha	Dissolving in bhṛṅgarāja svarasa	Bhāvana with kāsamarda svarasa		
Before śodhana (weight)	500 gm	500 gm	500 gm	500 gm		
After śodhana (weight)	350 gm	315 gm	300 gm	410 gm		

	Table 2 XRF analysis - Composition of Oxide (Unit - mass %)							
Element	Aśuddha kāsisa	Śuddha kāsīsa (ḍoļāyantra with bhṛṅgarāja svarasa)	Śuddha kāsīsa (doļāyantra with bhṛṅgarāja kvāthaḥ)	Śuddha kāsīsa (dissolving in bhṛṅgarāja svarasa)	Śuddha kāsīsa (bhāvana with kāsamarda svarasa)			
Ferric oxide (Fe2O3)	60.8%	65.171%	62.0%	65.183%	63.2%			
Sulphur trioxide (SO3)	36.9%	31.609%	28.0%	34.555%	28.5%			
Chromium oxide (Cr2O3)	0.444%	0.439%	0.682%	0.66%	0.849%			
Silicon dioxide (SiO2)	0.326%	0.111%	0.955%		0.923%			
Manganese oxide (MnO)	0.106%	0.024%	0.226%	0.264%	0.502%			
Calcium oxide (CaO)	0.0125%	0.3385%	0.521%	0.1385%	0.264%			
Potassium oxide (K2O)		3.246%	2.86%	0.525%	0.127%			
Cupric oxide (CuO)		0.37%	0.0220%		0.0257%			

	Table 3								
	XRF analysis - Composition of Element (Unit - mass %)								
	Aśuddha	Śuddha kāsīsa	Śuddha kāsīsa	Śuddha kāsīsa	Śuddha kāsīsa				
Element	kāsīsa	(doļāyantra with	(doļāyantra with	(dissolving in	(bhāvana with				
	Kasisa	bhṛṅgarāja svarasa)	bhṛṅgarāja kvāthaḥ)	bhṛṅgarāja svarasa)	kāsamarda svarasa)				
Iron	71.8%	74.58%	69.2%	76.46%	70.7%				
Sulphur	25.0%	16.57%	17.9%	20.75%	18.3%				
Chromium	0.513%	0.503%	0.745%	0.873%	0.930%				
Silicon	0.257%	0.657%	0.713%		0.691%				
Manganese	0.139%	0.299%	0.279%	0.459%	0.622%				
Calcium	0.0151%	0.5351%	0.595%	0.2151%	0.302%				
Potassium		5.23%	3.79%	0.87%	0.168%				
Copper		0.07%	0.0281%		0.0328%				

Discussion

After purification by four different methods, weight of kāsīsa before and after śodhana was compared. Loss of kāsīsa by svedana in dolāyantra might be due to heating procedure after complete dissolving of kāsīsa in bhrngarāja svarasa or bhrngarāja kvāthah. Maximum loss was seen in śodhana done by dissolving śuddha kās īsa in bhrngarāja svarasa as during its exposure to direct sunlight for drying, loss was observed due to its spillage. Minimum loss was seen in śodhana done by bhāvana with kāsamarda svarasa in khalvayantra as no spillage occurred during śodhana. Their XRF analysis was done. It showed that composition of iron, sulphur and their oxide were maximum in kāsīsa purified by dissolving it in bhrngaraja svarasa. Composition of chromium, manganese and their oxide were maximum in kasisa purified by bhāvana with kāsamarda svarasa. Composition of silicon, calcium and their oxide were maximum in kās isa purified by svedana in dolāyantra with bhrigarāja kvāthah. Composition of potassium, copper and their oxide were maximum in kasisa purified by svedana in dolāyantra with bhrigarāja svarasa.

Conclusion

It can be concluded that through XRF analysis, the main composition of kāsīsa which are iron and sulphur were maximum in kāsīsa purified by dissolving it in bhṛṅgarāja svarasa.

References

- 1. Vilas Dole and Prakash Paranjpe, *A textbook of Rasashastra*, P 24, Chaukhambha Sanskrit Pratishthan, Delhi, 2008.
- 2. https://en.m.wikipedia.org/wiki/X-ray_fluorescence (assessed date 02/01/2019)
- 3. Sadanand Sharma, *Rasatarangini*, with Prasadanee Vyakhya of Haridutta Shastri and Rasavidnyana Hindi Commentary by Ayurvedacharya Pandit Dharmananda Shastri, Verse 230, P 564, 11th Edition, Motilal Banarasidas Publication, Delhi, 2009.
- 4. Satpute A. D., *Rasaratnasamuccaya*, Verse 52, P 63, Chaukhambha Sanskrit Pratishthan, Delhi, 2006.
- 5. Indradev Tripathi, *Rasarnava*, Verse 82, P 99, Chaukhambha Sanskrit Series Office, Varanasi, 2001.

Authors

Manali Anil Visaria, Post Graduate Scholar, Department of Rasashastra and Bhaishajya Kalpana, Dr. G.D. Pol Foundation's, Y.M.T. Ayurvedic Medical College, Kharghar, Navi Mumbai, Maharashtra, India. Email: visariamanali@gmail.com
Sheela Pargunde, Professor and Head, Department of Rasashastra and Bhaishajya Kalpana, Dr. G.D. Pol Foundation's, Y.M.T. Ayurvedic Medical College, Kharghar, Navi Mumbai, Maharashtra, India.

Āryavaidyan, Vol. XXXII, No. 3, February - April 2019, Pages 45 - 49

An approach to lifestyle disorders and its management in children

Chethan Kumar V. K., Shubhangi Rathore and Harshitha M. S.

ABSTRACT: Lifestyle disorders are also called as the disease of civilization. As it takes a long time for a civilization to establish, similarly, these lifestyle disorders takes long time to occur in a healthy being and it becomes difficult to reverse the condition from diseased to healthy. The faulty daily habits like gorging on junk food, addiction to television and aversion to outdoor activities are the three major reasons. Also high fat and sugar rich diet, late night sleep and an inappropriate relationship with their environment lead to lifestyle disorders. The prevalence of childhood obesity, diabetes, hypertension and other life style disorders are increasing alarmingly in India, and are affecting much younger populations than in the West.1 Even the maternal lifestyle during pregnancy can affect the offspring to have such disorders. An association between such faulty lifestyle and lifestyle disorders were reviewed in different ayurveda and modern classics. Ayurveda offers several measures related to lifestyle which includes dinacarya (daily regimen), rtucarya (seasonal regimen), daivavyapāśraya cikitsa (divine/spiritual therapy), satvāvajaya cikitsa (psychobehavioral therapy), regular pañcakarma (regular internal bio-purification), rasayana (rejuvenative measures), sadvrtta (ideal routines) and ācāra rasāyana (code of good conducts) and āhāra and vihāra (dietary patterns and discipline of eating). These measures help to modify lifestyle, promote psychosomatic health and thus help in prevention and management of a wide range of lifestyle disorders and hence serve as measures for maintaining the well-being of children and a healthy nation. This article highlights the different lifestyle disorders in children and their management according ayurveda and modern classics.

Key words: Lifestyle, Lifestyle disorders, Eating habits, Childhood obesity, Prevention

Introduction

Lifestyle disorders are the disorders based on daily habits and an inappropriate relationship with the environment. They are also called as disease of civilization or non-communicable disease.^{2,3} A child is dependent for his nourishment when he is in mother's womb and therefore, maternal lifestyle also has an influence on the growth and development of a child.⁴ For this reason, āyurveda explains the regimen, a pregnant woman should follow to have a healthy offspring. Acarya have explained in detail regarding māsānumāsika paricarya (month wise regimen of a pregnant woman) by which the overall growth and development of the fetus can be taken care to have a healthy progeny.^{5,5a} If this monthly regimen is not followed by the pregnant mother, it may lead to fetal abnormalities in the antenatal period itself. With the

same concept, Barker hypothesis developed by the modern science explains fetal programming which is due to the effect of maternal under nutrition or maternal insult during critical period of the pregnancy. Dietary and living standards of a mother during pregnancy has a very significant effect on the fetus to develop disorders like obesity, insulin resistance and fetal alcohol syndrome which leads to conditions like diabetes mellitus and coronary heart disease in childhood.⁶ Childhood is the period of appropriate growth and development of the child. The three main reasons for children to get lifestyle disorder are gorging on junk food, addiction to television and aversion to outdoor activities.⁷ The excessive intake of high fat diet like pizza, burgers, etc. along with physical inactivity is the major cause for the development of childhood obesity which in turn leads to many other types of disorders like

diabetes, hypertension, hyperlipidemia, etc. Physical inactivity is the real killer, associated with a 'Sedentary death syndrome' of which obesity and type 2 diabetes mellitus are the most prevalent.^{8,9}

There are increased prevalence of obesity, because of decline in physical activity and awareness, together with irresponsible food marketing practices and the widespread use of cheap energy dense foods. ¹⁰ Hence, it is the need of the present era of technology and rapid urbanization with faulty lifestyle in children to prevent these disorders through holistic approach.

Literary review

Childhood obesity is a major public health problem of the modern world which has shown increasing trends globally in the recent years. WHO has mentioned it as one of the most serious public health challenges in the 21st century due to its rapidly increasing prevalence and tracking seen till adulthood. Out of the predicted 1.5 billion overweight people in 2015, it is estimated that children will constitute around 10% of which 75% are from developing countries. Parallel rise of conditions like dyslipidemia, hypertension, abnormal glucose tolerance and reduced health related quality of life is seen amongst pediatric age group.

Authors Booth and Lees have reported that based on declining activity levels with children and adolescents now spending as much as 45 hours each week in sedentary screen based pastimes, every child in the United States will be obese by 2044.9 Obesity is characterized by increased storage of fatty acids in an expanded adipose tissue mass and in peripheral tissues such as the skeletal muscle and liver which is explained as medoroga in āyurveda where the causes are explained as physical inactivity, intake of sweet and high fat diet leading to the development of insulin resistance, explained by the ācārya as prameha pūrvarūpa.¹³ A study by Borg and colleagues states that a high fat diet could literally leave you with 'fat on brain'. Studies have shown in both animals and humans that consuming excessive amounts of fat in

the diet leads to an increased accumulation of lipid in peripheral tissues which are not designed for fat storage, particularly the skeletal muscle and the liver. Ectopic fat storage which interferes with their ability to function normally leading to co-morbidities associated with diet induced obesity, in particular insulin resistance.¹⁴

Type 2 diabetes mellitus is due to the combination of insulin resistance with relative insulin deficiency and is becoming prevalent among children due to rise in childhood obesity. 6a Excessive intake of heavy, unctuous, saline substances, use of new rice or fresh wine, excessive sleep, no mental or physical exercise with sedentary habits leads to augmentation of pitta, meda, kapha and māmsa which obstructs the vāta and drives it down to urinary system leading to madhumeha (diabetes mellitus). 15 Ācārya have described two types i.e.; Jāta pramehi and sthūla pramehi and by looking on to the etiological factors and the features explained they can be compared with type 1 and type 2 diabetes mellitus respectively which are now seen in children. 15a

It is now considered that most of the chronic disorders like obesity, diabetes mellitus, hypertension bronchial asthma, coronary artery diseases, COPD (chronic obstructive pulmonary diseases), chronic liver diseases, psoriasis, arthritis, etc. are resulted due to faulty lifestyle. 16 Therefore, lifestyle modification is to be considered as major criteria for the prevention and management of such type of disorders. Ayurveda offers a wide variety of dietary supplementation and a range of non-pharmacological measures for prevention and management of lifestyle disorders. There is a great need of time to globalize dietary supplementation and non-pharmacological measures as described in ayurveda system of medicine to promote the health and to reduce the disease burden on the society.

Discussion

Āyurveda offers holistic approach towards prevention and management of diseases. Āyurveda

intervention targets towards complete physical, psychological and spiritual wellbeing, which makes it a wonderful option in treating lifestyle disorders. Ayurveda provides great options in the form of proper dietary management, lifestyle modifications, measures for internal bio-purification and rejuvenation.

Lifestyle medicine is defined as the application of environmental, behavioral, medical and motivational principles to the management of lifestyle-related health problems in a clinical setting. ¹⁷ A healthy life style includes a proper balanced diet and physical activity which must be adopted to combat these diseases.

Ayurveda described dinacarya (daily regimen) and rtucarya (seasonal regimen) which include dietary and lifestyle modification for an individual depending on his prakrti (psychosomatic constitution) to maintain the health and hence, to prevent the diseases due to lifestyle modifications. Ayurveda explains various measures for the management of lifestyle disorders which plays a significant role to maintain health and for preventing diseases like; āhāra (diet/dietary supplementation), daivavyapāśrayacikitsa (divine/spiritual therapy), satvāvajayacikitsa (psycho-behavioral therapy), dinacaraya (daily regimen), rtucarya (seasonal regimen), pañcakarma (five technologies of internal bio-purification), rasāyana (rejuvenative measures), the sadvṛtta (ideal routines) and ācāra rasāyana (code of good conducts).18

WHO developed preventive Global strategy of diet, Physical activity and health (DPAS) in 2004 to overcome lifestyle disorders. ¹⁹ Āhāra and vihāra play an important role in the life according to āyurveda. In āyurveda, āhāra and vihāra have been given utmost importance for better living, health and wellness. Āyurveda emphasizes more on āhāra and is considered as prāṇa (basis of life). ²⁰ Āhāra has been described as one of the trayopastambha (three subsidiary pillars) of life. ²¹ Similarly, diet is

considered as vital for a human body as it provides the basic nutrients and promotes longevity. \overline{A} yurveda always emphasizes on consuming healthy and nutritious diet for maintaining good health.

As per the view point of ayurveda, both the living human body and the diseases afflicting it are the products of āhāra. Use of hitāhāra (wholesome diet) promotes health and longevity and ahitāhāra (unwholesome diet) promotes manifestation of different disorders.²² Unfortunately in modern era, the concept of hitāhāra is continuously being ignored leading to the development of lifestyle disorders. Ayurveda offers different pathyāpathya (do's and don'ts) regarding diet/dietary supplementations which definitely help in the prevention and management of a wide range of lifestyle disorders. It has been explained by the ācārya to take guru (heavy to digest) and apatarpana (non-nourishing) āhāra for the management of obesity as it is explained as santarpanottha-janya-vyādhi (disease due to over nourishment).23

Vyāyāma (exercise) is said to be a preventive management for the disorders due to sedentary lifestyle. Physical activity normalizes elevated leptin level in obesity.²⁴ In previous studies exercise has proved to be an effective approach for promoting fat oxidation, reducing triglyceride content in skeletal muscle and improving peripheral insulin sensitivity.²⁵

In addition to food and diet, āyurveda has a separate concept of medicinal dietary supplements in the context of rasāyana (rejuvenative measures). Rasāyana can be used as nutritional supplement as well as medicine depending upon its various types. Most rasāyana act by promoting the agnibala, acting as direct nutrients and by way of sroto-prasādana (purification of body channels), resulting in an improved nutritional status which leads to an improved quality of dhātu or body tissues. ²⁶ Various studies on rasāyana suggest their action as immunomodulator, adaptogenic, antioxidant, nootropic and antistress. ²⁷

Dinacarya (daily regimen) is very important in day to day life to maintain biological clock. Therefore, one has to stay aware about this daily regimen for day to day promotion of health, boost immunity and prevention from lifestyle disorders.

Each rtu (season) has different effects on the body as well as on the environment. Ayurveda has depicted various regimens (carya), regarding diet and lifestyle to adjust with the seasonal enforcement easily without altering body homeostasis. Hence, rtucarya is a very important aspect of preventive measure for various illnesses including lifestyle disorders as mentioned in āyurveda.

Āyurveda describes code of good conducts under the heading of sadvṛtta and ācāra rasāyana. It is a protective factor for maintaining mental health. Furthermore, community participation and civic engagement are associated with better self-reported mental health.

Lifestyle disorders are very common in the present era due to unawareness and ignorance towards proper daily regimen, seasonal regimen and good code of conducts. The therapeutic application of āhāra and vihāra as described in āyurveda is very vast and more scientific. It needs further validation in the management of lifestyle disorders as per the need of present era.²⁸

Conclusion

In present era, due to the rapid advancements in technology and rising influence of western lifestyle, parents are unaware about the lifestyle as mentioned in āyurveda. So they are not able to train their children to follow a proper lifestyle mentioned by the ācārya in āyurveda. Children develop the habit of improper lifestyle with excessive eating especially the junk food or fast food along with the addiction to television which makes them to be physically inactive. Due to these reasons, they start to develop lifestyle disorders like childhood obesity, diabetes mellitus,

hypertension, hyperlipidemia etc. which affect their growth and development in a significant way. As children are the wealth of a nation, it is our responsibility to guide the parents as well as the children in a holistic way to follow dinacarya, rtucarya, sadvrtta and ācārarasāyana, so as to lead a healthy life and a healthy nation.

References

- 1. https://www.ncbi.nlm.nih.gov
- 2. Carrera-Bastos P., Fontes-Villalba M., O Keefe J.H., Lindeberg S. and Cordain L., The western diet and lifestyle and diseases of civilization, *Research Reports in Clinical Cardiology*, Mar 9;2:15-35, 2011.
- 3. Centers for Disease Control and Prevention (CDC), Overview of non-communicable diseases and related risk factors.
- 4. Mudor H. and Bunyarit F., A Prospective of nutrition intake for pregnant women in Pattani, Thailand, *Procedia-Social and Behavioral Sciences*, 2013, Oct 10;91:179-84, Elsevier.
- 5. Tewari Premvati, *Ayurvediya Prasuti-Tantra evam stri roga*, Part I, P 143, 2nd Edition, Chaukhamba Orientalia, Varanasi, 2009.
- 5a. Ibidem., Part I, P 148.
- 6. Gupta Piyush, Menon P.S.N., Ramji Siddarth and Lodha Rakesh, *PG Textbook of Pediatrics* (3Vols.), 3: 2413, Jaypee Publishers, New Delhi, 2015.
- 7. Pandey Jhimli Mukherjee, Lifestyle diseases now target kids. Schools on alert as junk food, TV addiction and aversion to outdoor activities lead to rise in Cardiac disorders among children, *The Times of India*, P 2, Kolkata, 2010.
- 8. Sjöström S., Snögren A.K., Koochek A. and Liljeberg E., Factors influencing the choice of oral nutritional supplements prescribed by Swedish dietitians, Vol. 60, In 11th Nordic Nutrition Conference Gothenburg 20-22 June 2016, 2016.
- 9. Lees S.J. and Booth F.W., Sedentary death syndrome, *Canadian Journal of Applied Physiology*, Aug 1;29(4):447-60, 2004.
- 10. Taylor P.D., Can exercise prevent coronary artery disease even on a high fat diet? *The Journal of physiology*, 590(17), P 4125-4126, 2012.

- 11. Hurt R.T., Kulisek C., Buchanan L.A. and McClave S.A., The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists, *Gastroenterology and Hepatology- The independent peer reviewed journal*, New York, Dec;6(12):780-92, 2010.
- 12. World Health Organization, Global status report on non-communicable diseases 2015, *World Health Organization*, 2015.
- 13. Madhava, *Madhavanidana*, Part II, P 34, Chawkhambha Sanskrit Sansthan, Varanasi, 2009.
- 14. Borg M.L., Omran S.F., Weir J., Meikle P.J. and Watt M.J., Consumption of a high fat diet, but not regular endurance exercise training, regulates hypothalamic lipid accumulation in mice, *The Journal of Physiology*, Sep 1;590(17):4377-89, 2012.
- 6a. Ibidem., 3: 2375.
- 15. Agnivesa, *Carakasamhita*, revised by Caraka and Dridhabala with the Ayurvedadipika Commentary of Cakrapanidatta, Edited by Harishchandra Singh Kushwaha, P 183, Chaukhamba Orientalia, Varanasi, 2005.
- 15a. Ibidem., P 187.
- 16. Divo M., Cote C., de Torres J.P., Casanova C., Marin J.M., Pinto-Plata V., Zulueta J., Cabrera C., Zagaceta J., Hunninghake G. and Celli B., Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease, *American Journal of Respiratory and Critical Care Medicine*, 2012 Jul 15;186(2):155-61.
- 17. Guyatt G., Rennie D., Meade M.O. and Cook D.J., *Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice*, AMA Press, Chicago IL, Feb 1, 2002.
- 18. Thakkar J., Chaudhari S. and Sarkar P.K., Ritucharya: Answer to the lifestyle disorders, *Ayu: An International Quarterly Journal of Research in Ayurveda*, Oct;32(4):466, 2011.

- 19. World Health Organization (WHO), Global strategy on diet, physical activity and health: *World Health Assembly* 57.17, Geneva, Switzerland, 2004.
- 20. Guddoye G. and Vyas M., Role of diet and lifestyle in the management of Madhumeha (Diabetes Mellitus), *Ayu: An International Quarterly Journal of Research in Ayurveda*, Apr;34(2):167, 2013.
- 21. Singh S., Principle and Practice of Nutrition and Dietetics in Ayurveda, *International Journal of Research in Pharmacy and Biosciences*, Aug 7;1, 2015.
- 22. Swami Sadashiva Tirtha, *The Ayurveda encyclopedia: Natural secrets to healing, prevention, and longevity*, Sat Yuga Press, 2007.
- 23. Chandola H.M., Lifestyle disorders: Ayurveda with lots of potential for prevention, *Ayu: An International Quarterly Journal of Research in Ayurveda*, Jul;33(3):327, 2012.
- 24. Booth F.W., Roberts C.K. and Laye M.J., Lack of exercise is a major cause of chronic diseases, *Comprehensive Physiology*, Apr 1, 2012.
- 25. Muhlhausler B.S., Fat on the brain, *The Journal of Physiology*, Sep 1;590(17):4121, 2012.
- 26. Satyapal S., Tripathi J.S. and Rai N.P., An integrated dietary approach for the management of dermatological disorders, *International Journal of Research in Ayurveda and Pharmacy*, 2015.
- 27. Pansare T.A. and Thombare P., Review on Rasayana (Rejuvenative) Plants of Various Nighantus (Ayurvedic Materia Medica), *International Journal of Ayurvedic and Herbal Medicine*, 6:6 (2016) 2369 2384.
- 28. Morandi A., Tosto C., Sartori G. and Roberti di Sarsina P., Advent of a Link between Ayurveda and Modern Health Science: The Proceedings of the First International Congress on Ayurveda, 'Ayurveda: The Meaning of Life Awareness, Environment, and Health' March 21-22, 2009, Milan, Italy, Evidence-Based Complementary and Alternative Medicine, 2010 Oct 17;2011.

Authors

Chethan Kumar V. K., Professor and Head, Department of Kaumarabhritya, Taranath Government Ayurvedic Medical College, Ballari, Karnataka. Email: drchethankumar@gmail.com

Shubhangi Rathore, Consultant, Medanta Ayurveda Hospital, Medanta The Medicity, Gurugram, Haryana.

Harshitha M. S., Assistant Professor, Department of Rachana Shareera, Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Udupi, Karnataka.

Āryavaidyan, Vol. XXXII, No. 3, February - April 2019, Pages 50 - 59

Toxicity profile of Malla sindūra- a kūpīpakva rasāyana

Pallavi M., Pavan Kumar and Doddamani M. S.

ABSTRACT: Malla sindūra (MS) is a unique rasa yoga, with pārada, gandhaka and malla prepared by kūpi pāka method having indications in vātaroga, āmavāta, visūcikā, etc. In this study the pharmaceutical processing as per texts and various physico-chemical and instrumental analysis of malla sindūra was carried out. The objectives of the study included review of malla sindūra, malla, pārada, gandhaka and other associated drugs. Preparation of malla sindūra kajjali (MSK) and malla sindūra as per classical reference, physico-chemical analysis of malla sindūra kajjali and malla sindūra and evaluation of toxic effect of malla sindura on albino rats by acute and sub acute oral toxicity method were done. Pharmaceutical study included (i) the extraction of pārada from hingula by ūrdhva pātanayantra (ii) Gandhaka śodhana in godugdha by subjecting to kūrmaputa by bhūdharayantra method (iii) Malla śodhana in kāravellaka svarasa by subjecting to svedana in dolāyantra for two yāma and (iv) Preparation of MSK. MSK was prepared from pārada, gandhaka and malla in the ratio of 1:1:1/2 and subjected to kūpipāka in vālukāyantra for 56 hrs. The kanthastha product was collected. In the analytical study physical, chemical and instrumental analysis was carried out for MSK and MS. MS is a unique kūpipāka preparation, which is a sāgni, sagandha mūrcchana of pārada, gandhaka and malla in the ratio of 1:1:1/2 through kramāgni pāka for 36-48hours. Sodhana of each ingredient will modify the raw drug into its safe, bioactive, therapeutic form and is an essential preliminary step for all the pharmaceutical procedures of kūpi pakva rasāyana. In the preparation of MS, MSK was subjected to kramāgni pāka in vālukā vantra. The process completed in 56 hrs. Chemical tests denoted that the drug does not contain free mercury and sulphur which proves its safety. A major percentage of mercury was in mercuric form; sulphur in sulphide form and arsenic in arsenate form. Overall assessment was done by observing the analytical parameters and it was found that MS is safe at therapeutic dose.

Key words: Mallasindūra, Kūpīpāka, X-ray Diffraction, Fourier transmission infrared spectroscopy

Introduction

Rasacikitsa is an important stepping stone in the development of āyurveda. Rasaśāstra deals with the preparations of medicines mainly with the help of mercury, minerals, metals and herbs. There are four types of rasauṣadhi which are described in Rasaśāstra. Kharaḷīya rasāyana, parpaṭi rasāsyana, kūpīpakva rasāyana, pottali rasāyana.

Indian alchemy developed a wide variety of chemical processes for the transmutation of metals and preparation of elixir of life, in which mercury occupied a prime position. The literature on rasaśāstra is perceptibly voluminous and methodical in the presentation of a variety of processes whose number is countless. Of these processes, kūpīpakva rasāyana deserves special mention because of its minimal

dosage, augmenting effect and long lasting potency.

Malla sindūra¹ is one of the important classical kūpīpakva rasāyana containing hiṅgulottha pārada, śuddha gandhaka and śuddha malla in 1:1:1/2 proportions. It is sagandha, sāgni, bahirdhūma, kanṭhastha kūpīpakva rasāyana potentiated with agni samskāra for 36-48 hours. The process converts the metal into a chemical compound with necessary medicinal benefits like in the treatment of vātaroga, āmavāta, visūcikā, etc.

Materials and methodes

Drug review

All together seven varieties of malla sind \bar{u} ra has been mentioned in classics. All these have different ingredients but the similarities being all are $k\bar{u}p\bar{i}$

pakva rasa. Pārada, gandhaka and malla are the common ingradients in all types of malla sindūra.

Ingredients: Śuddha malla : 5 tola, śuddha pārada : 10 tola, śuddha gandhaka : 10 tola and kumārī svarasa : O.S.

Procedure: The ingredients were taken in the said quantity to prepare kajjali. After attaining kajjali siddhi lakṣaṇa, fine powder of śodhita malla was added and bhavana with kumārī [*Aloe vera* (L.) Burm.F.] svarasa was done and allowed to dry. It was filled in a kācakūpi and was kept in vālukāyantra by giving kramāgni.

Materials

Raw drugs: Major and associated raw drugs. Equipments: Major and associated equipments. Collection of raw materials: Raw drugs which were having similar grāhya lakṣaṇa as mentioned in the classics were collected from the market.

Major drugs

Malla: Malla is a crystalline or amorphous substance, white in colour. Its powder resembles the flour of wheat but is much heavier. The surface of malla has a peculiar shine and sometimes there occurs a yellowish tinge which meets with the qualities of grāhya malla.²

Hingula: It is dark red in colour, heavy with silvery white shining lines on the surface.³

Gandhaka: It is yellow, crystalline with smooth surface and strong sulphur odour.^{3a}

Place of procurement

Malla: Amrith Kesari, Bangalore.

Hingula: Mamata Herbals, Thane, Maharastra

Gandhaka: Jogappa Shanbhaug, Udupi.

Associated drugs


Kāravellaka (*Momordia charantia* L.) svarasa for śodhana of malla, nimbū [*Citrus limon* (L.) Osbeck] svarasa for hiṅgulottha pārada, haridrā (*Curcuma longa* L.) cūrṇa for hiṅgulottha pārada, milk for gandhaka śodhana and kumārī svarasa for bhāvana of MSK.

Main equipments: Khalva yantra, ūrdhvapātana yantra, kūrmapuṭa and vālukā yantra.

Methods

The whole method of preparation includes;

1. **Śodhana of raw materials**: Śodhana of malla was in kāravellaka svarasa by svedana method⁴ and śodhana of gandhaka in godugdha by kūrma puṭa method.⁵ Figure 1.



- 2. **Extraction of pārada from hiṅguḷa**: It was done by ūrdhvapātana method.⁶ Figure 2.
- 3. **Preparation of MSK**: Preparation contained 1part of hingulottha pārada and 1part of śuddha gandhaka. Trituration was done till kajjaļī siddhi lakṣaṇa was obtained. Later, half part of śodhita malla
- (finely powdered) was added and triturated for about 6 hours for a homogeneous mixture of MSK. Later, bhāvana was given to this kajjaļi with kumārī svarasa and was dried completely in shade. Figure 3 and 4.
- 4. Preparation of MS¹
- 1. Pūrvakarma (Figure 5)

Figure 2 Hiṅgulottha pārada nirmāṇa



Figure 3 Malla śodhana



Pārada + Gandhaka

Mardana

Kajjaļi


Adding kumārīsvarasa to kajjaļi

to kajjaļi

to kajjaļi

Figure 4
Prepartion of Malla sindūra kajjaļi

Figure 5 $P\bar{u}rvakarma$ in the preparation of Malla sind $\bar{u}ra$




a. **Preparation of kācakūpī**⁷: Amber coloured glass beer bottle of 650 ml was taken. The bottle was cleaned and completely dried. At the base of the bottle paste of gopīcandana (multani mitti) was applied. A cloth smeared with gopīcandana measuring 6cm x 6cm width and breadth was covered and dried completely. Another cloth smeared with gopīcandana measuring 116cms x 4cms length and breadth was covered in circles, starting from the bottom of the bottle upto mouth of the bottle and was allowed to dry completely.

After completion of 7 layers, one layer of red clay was smeared. Later, one more layer of gopicandana smeared cora cloth was applied and kept for drying. In this way nine layers were covered over the surface of the bottle.

- b. Filling of kajjali in kācakūpī
- c. Placing of kācakūpī in vālukā yantra
- 2. Pradhānakarma (Figure 6)
- a. Heating schedule (Kramāgni tāpa). Table 1.
- b. Observation and recording of temperature.
- c. Corking kācakūpi and self-cooling of theapparatus.
- 3. Pascātkarma (Figure 7)
- a. Removal of kācakūpi from vālukāyantra.
- b. Breaking of kācakūpi.
- c. Collection of final product.

Analytical study: Physical tests MSK and MS (Table 2 and 3), Chemical tests MSK and MS (Table 4), X-ray diffraction (Table 5), Particle size of MSK and MS (Table 6), EDX of MSK and MS (Table 7),

Figure 6
Pradhānakarma in the preparation of Malla sindūra



Aryavaidyan

Figure 7
Pascātkarma in the preparation of Malla sindūra

and The Namburi Phased Spot Test (NPST) of MSK and MS (Table 8).

Toxicological study

Acute toxicity study8

- According to OECD 425 GUIDELINES, dosing was started with 175mg, as first rat did not showed any toxic symtoms.
- The next animals were dosed with 550mg, 2000mg, 2000mg and 2000mg, according to staircase method (AOT software).
- Further dosing was stopped following the guidelines
- No morbidity and mortality was seen
- The data was fed into AOT software to obtain LD50 value with confidence limit.
- Hence, the LD 50 is greater than 2000mg/kg.

Sub-Acute Study: 28days (AYUSH rule 170)

- Test drug: Malla sindūra.
- Dose selection: Human therapeutic dose of MS 62.5mg.
- The dose administered in different groups of

sub-acute study. Table 9

- Route of administration : oral
- Duration of the study : 28 days
- Statistical analysis: one way ANOVA followed by Dunnett's multiple 't' test.
- Animals:-Wistar strain albino rats of either sex weighing between 150-250g.
- Drug Administration: 28 days

Parameters studied

Changes in body weight: recorded once a week

Ponderal changes: The weight of important organs like brain, heart, liver, spleen, lungs, kidney, jejunum, testis and uterus was recorded.

Hematology: The following parameters were measured using automated cell counter: hematocrit, hemoglobin concentration, erythrocyte count, total and differential leucocyte count and platelet count.

Biochemical parameters: Glucose, urea, creatinine, total protein, albumin, globulin, activity of the enzymes SGOT, SGPT and ALPase., serum cholesterol, triglycerides, direct bilirubin and total bilirubin were determined in plasma or serum.

			T 11 1
			Table 1 Heating schedule (Kramāgni tāpa)
			Mrdvagni
_		Temperature	·
Date	Time	in °C	Observations
Day 1	05.30am	26	Agni started.
	06.30am	247	No fumes inside kūpi, bottom of kūpi could be seen clearly with torch.
	07.30am	275	-
	08.30am	213	Slight white fumes were seen inside kūpi.
	09.30am	193	-
	10.30am	195	Thick dense whitish fumes inside the kūpi.
	11.30am	210	The fumes became dense, can't see the bottom of kupi with torch.
	12.30pm	252	Still dense whitish fumes found inside kūpi.
	01.30pm	253	Śīta śalāka inserted kajjaļi started melting, it was sticky in consistency.
			Madhyamāgni
Day 1	02.30pm	253	Mild sulphur smell appreciated. Yellowish dense fumes ++
	03.30pm	265	
	04.30pm	315	Strong sulphur odour appreciated.
	06.30pm	340	Śīta śalāka was inserted, kajjaļi was slight sticky.
	07.30pm 08.30pm	349 329	Dense yellow fumes observed. Bottom of kūpi was not visible.
	11.30pm	350	Yellowish particles deposited around the neck of kūpi.
Day 2	12.30am	368	Dense gandhaka fumes found. Bottom cannot be seen with torch.
Day 2	04.30am	408	Melting of kajjali started.
	05.30am	452	Orange yellow fumes ++
	06.30am	470	Dense yellow fumes + + +
		1 11 11 11 11 11 11 11 11 11 11 11 11 1	Tīvrāgni
Day 2	10.30am	488	Śīta śalāka inserted at half the level of kūpi. At this level liquified kajjaļi
			adhered-kajjali is boiling.
	11.00 am	488	Hot śalāka was inserted to clear the block. Whitish fumes observed with
	11 20	401	sulphur smell.
	11.30am	491	Adhering of liquefied kajjali at the mouth of kūpi.
	12.30pm	517	Deposition of kajjali at the mukhabhāga.
	01.30pm	540	Hot śalāka inserted. Blue flame partially observed as the kajjali started adhering to the mouth of the kūpi.
	02.30pm	555	Hot śalāka was inserted three times block was cleared off. Bluish flame at the
	02.5 opin		mouth was found.
	03.30pm	582	-
	04.30pm	578	-
	05.30pm	573	Onset of sūryodaya lakṣaṇa.
	06.30pm	567	Sūryodaya lakṣaṇa +, Sulpher fumes +++
	07.30pm	582	-
	08.30pm	592	Hot śalāka inserted. Blue flame seen at the kantha bhāga.
	09.30pm	565	-
	10.30pm	583	Hot śalāka inserted. Blue flame seen at the kantha bhāga.
	11.30pm	580	Sulpher fumes reduced

 Taryavaidyan

Day 3	12.30am	582	Śīta śalāka was introduced into kūpi and kajjaļi adhesion was seen.
	01.30am	607	-
	02.00am	605	-
	02.30am	601	Sūryodaya lakṣaṇa ++, Thick fumes decresed, śita śalāka inserted and upper
			1/3 rd was adhering and lower 2/3 rd was dry product when rubbed in khalva it
			showed reddish colour.
	03.30am	597	-
	04.30am	589	-
	05.00am	615	Product when rubbed in khalva reddish color seen.
	05.30am	600	Copper coin test was done. It was positive ie copper coin was kept over the
			mouth of the bottle, the surface of the coin turned into greyish white in colour.
			No flames observed.
	05.45am		
	То		
	06:45 am	570	Preparation for corking - wood removed, vālukā surrounding the neck
			region of kūpi was removed. Corking was done with the help of gopicandana
			smeared cloth. It took about 45min.
	07:00 am	343	Fire given after corking
	08.00am	423	
	То	То	
	11.30pm	180	As corking was done, no visible observations were possible.

Table 2 Physical tests of MSK and MS				
Physical test	MSK	MS		
Colour	Black	Reddish orange		
Odour	Odourless	Odourless		
Taste	Slightly pungent (characteristic)	Slightly pungent		
Touch	Amorphous	Amorphous		

Table 3							
Paramete	Parameter tests of MSK and MS						
Parameter	MSK	MS					
рН	5.61 ± 0.10	6.00 ± 0.10					
Total Ash value	0.16 %	0.13 %					
Acid Insoluble Ash	0.50%	0.75%					
Water Soluble Ash	1.45%	1.50%					
Loss on Drying	2.70 %	Nil					

Table 5					
	X-Ray diffraction				
Parameters	MSK	MS			
Name	Arsenic oxide, metacinnabar	Cinnabar, Arsnolite			
Composition	As ₂ O ₃ , HgS	HgS, As ₂ O ₃			
Crystal system	Cubic ,Cubic	Hexagonal, Cubic			

Table 4				
Chemical tests of MSK and MS				
Contents	MSK	MS		
Total Mercury	45.25 %	51.55 %		
Mercurous mercury	13.45%	11.45%		
Mercuric mercury	30.50%	40.10%		
Free Mercury	1.30%	Nil		
Total Sulphur	22.13%	13.55%		
Free Sulphur	1.25%	Nil		
Sulphide	18.35%	12.80%		
Sulphate	2.53%	1.75%		
Total Arsenic	7.12%	9.45%		
Arsanate	5.10%	6.50%		
Arsanite	2.02%	2.95%		

Table 6			
Particle size of MSK and MS			
Name of the sample	Mean particle size		
MSK	550.0 nm		
MS	393.3 nm		

Table 7				
EDX of MSK and MS				
	Concentration in %			
Elements Found	MSK	MS		
S	29.10	17.08		
As	19.41	14.51		
Hg	37.13	56.62		




Table 9 Dose administered in different groups of sub-acute study					
Group	No. of animal	Drug	Dose	Duration	Purpose
Control group 1	10	Water	Sufficient	28 days	To serve as control group
Trial group 2	10	MS	5.62 mg/kg. (Therapeutic dose)	28 days	To serve as trial group
Trial group 3	10	MS	28.12 mg/kg. (5 times of Therapeutic dose)	28 days	To serve as trial group
Trial group 4	10	MS	56.25 mg/kg (10 times of Therapeutic dose)	28 days	To serve as trial group

Discussion

Hingulottha pārada

- Citric acid helps for the disintegration of HgS and weaken the bond and hence, facilitates dissociation of mercury.
- Mercury has a low boiling point of 356.9°C. When heat is applied oxygen combines with sulphur to form sulphur dioxide and mercury is liberated in the vapour form at a temperature above its boiling point.
- Impurities like nāga, vanga, etc., having high boiling point do not sublimate and remain at the bottom.

Malla śodhana

• The phytochemicals such as charantin, polypeptides, Ca, Fe, Mg, etc. present in kāravellaka svarasa might be reducing the toxicity of malla or be doing a chemical detoxification. Thus making malla a safe, non-toxic and bio acceptable drug.

• The bhedana property of kāravellaka might be having some role in converting viṣa guṇa of malla into medicinal values.

Discussion on toxicology study

It was observed that there is a significant decrease in the mean cell volume (MCV) in TED group and a significant decrease in the mean cell haemoglobin (MCH) in all the TED group.

Thirteen biochemical parameters were studied, out of which significant change was observed in Group TEDx5 and significant increase in SGPT and significant decrease in ALP were observed as compared to control group.

In Group TEDx10, significant increase in sugar, APL, albumin, cholestrol and triglycerides; and significant decrease in SGPT, urea were observed compared to control group.

Liver function test: SGOT and SGPT activity was found decreased in all groups. The observed effect may not be considered as indicative of any underlying pathology.

The weight of lungs, heart, liver, kidney and spleen were not affected to significant extent indicating good tolerance of these tissues. Jejunal weight was found significantly decreased. This may be indicative of loss of tissue. Histological observation showed epithelial layer disruption at all the dose levels but it was comparatively less at higher dose level. Decrease in uterine weight and increased testis weight was analyzed. Histology revealed normal profile of both.

Food intake: TED x10 dose significant increase was observed in all the 4 weeks. This shows the agnid \bar{i} pana property of MS.

Conclusion

Even though malla sindūra has different pharmaceutical procedures in rasaśāstra classics, in the present study, it has been prepared according to Rasatantra sāra va Siddhaprayoga saṅgraha. It is a sāgni, sagandha, bahirdhūma and kaṅṭhastha kūpī pakva rasāyana, containing pārada, gandhaka and malla in 1:1:1/2 proportions. The kajjaļi prepared out of them was subjected to kūpīpāka in vālukāyantra for 56hrs through kramāgni. Yield obtained was 71.11%.

The test drug MS was studied to elucidate the acute and sub-acute toxicity profile. Acute toxicity study showed a LD_{50} of greater than 2000mg/kg body weight. In sub-acute study MS was found to be well tolerated even at higher dose level.

Overall assessment was made by observing the hematological, biochemical and food conversion parameters. MS is safe at therapeutic dose, 5 times of therapeutic dose and up to the 10 times of therapeutic dose. Its careful administration is not likely to cause any serious toxic outcomes at the therapeutic dose levels.

References

- 1. Anonymous, *Rasatantra sara va Siddaprayoga sangraha*,, Prathama Khanda, P 261-264, 16th Edition, Colleda-Ajmeer, Krishna Gopal Ayurved Bhavan, 2003.
- 2. Sarangadhara, *Sarangadharasamhita*, Edited by Srikantha Murthy, 2nd Vol., 12th Chapter, P 159, 1st Edition, Chaukambha Orientalia Publication, Varanasi, 1984.
- 3. Acarya Sri Madhava, *Ayurvedaprakasa*, Edited by Gulrajsharma Mishra, Hindi Commentaries, 2nd chapter, Verse 71, P 273, Reprint edition, Chaukhambha Bharati Acadamy Publication, Varanasi, 2007.
- 3a. Ibidem., 2nd Chapter, Verse 20, P 261.
- 4. Acarya Yasodhara, *Rasaprakasha sudhakara*, Siddhiprada Hindi Commentary, Translated by Dr. Siddhinandan Mishra, 1st Chapter, Verses 17-20, P 5, 2nd Edition, Chaukhambha Orientalia, Varanasi, 1998.
- 5. Krishnan Vij, *Textbook of Forensic Medicine and Toxicology Principles*, P 818-819, 2nd Edition, B.I. Churchill Livingstone, New Delhi.
- 6. Sri Sadananda Sharma, *Rasatarangini*, Edited by Kasinatha Sastri, Taranga Verses 38-42, P 82, 11th Edition, Motilal Banarasidas Publication, New Delhi, 1979.
- Sri Vagbhatacarya, Rasaratnasamucchaya, Edited by Pandit Sri Dharmanandana Sharma, 10th Chapter, Verse 6, P 146, 2nd Edition, Motilal Banarasidas Publication, Varanasi, 1996.
- 8. www. Oecd-iliberary.org 15/12/2016

Authors

Pallavi M., Assistant Professor, Department of Rasashastra and Bhaishajyakalpana, Shri Jagadguru Gavisiddheshwara Ayurveda Medical College and Hospital, Koppal, Karnataka.

Pavan Kumar, Chief Physician, Om Prakash Ayurveda Clinic and Panchakarma Centre, Saidapur, Yadgir tq., Karnataka. Doddamani M. S., Principal, Govt. Ayurvedic Medical College and Hospital, Shivamoga, Karnataka.



Āryavaidyan, Vol. XXXII, No. 3, February - April 2019, Pages 60 - 61

Katukka (Harītakī)

Dhanvantari is the first medical journal in Malayalam published every month by Vaidyaratnam P. S. Varier from Arya Vaidya Sala uninterruptedly for 23 years from 1903 to 1926. This clinical note was published in its column on Book No. 8, 1086 Minam Malayalam Era (1911 CE), Article No. 10, Page 93A.



An effective purgative drug without any side effects that can be administered irrespective of age. But to our dismay, some are of the opinion that it is not as effective as it was earlier. This may be because of the image of stronger drugs or may be because of its faulty usage. One can in no way blame this drug for these reasons! Again, we should not underestimate the power of this drug.

An anonymous saying prevalent among some writers is that this harītakī (*Terminalia chebula* Retz.) was born from the elixir, that Lord Indra was consuming. So one need not be surprised if it is so because such are the properties that this drug displays.

The Sanskrit term harītakī means that this is seen in the abode of Lord Śiva and is green. These exaggerations cannot be ruled out because such great are the properties that this drug displays! A mention of this quote is very much appropriate here without which this article may not be complete.

Harītakī manuṣyāṇām māteva hitakāriṇī | Kadācit kupyati mātā nodarasthā harītakī |

The fact is clearly stated here. Normally a person who takes a purgative has the following symptoms such as fatigue, stomach ache and discomfort. Besides, a small variation in the dose (if it exceeds) may be a cause for concern. But it is safe to administer harītakī as one need not worry about these side effects. It is very safe to use harītakī. Unlike the other drugs even if one does not purge, there is no side effect to be alarmed of. There is no dought that the person who coined the quote has sufficient researches to his credit!

One can find innumerable formulae with harītakī but it is more effective as a mild laxative. Here I shall mention one or two important formulae with harītakī

that are used as a mild laxative.

Vaiśvānaram, Intuppukānam, Hutabhugādi, Pathyāmodakam and Gomūtraharītakī are very effective mild purgatives. Here again, Vaiśāvanaram and Intuppukānam are administered in agnimāndya (poor digestion) where as Hutabhugādi for arśa (piles) and Gomūtraharītakī for śopha (water retention/oedema). Pathyāmodakam, on the other hand can be administered in almost all kinds of diseases as a mild laxative. Laxatives are good appetizers. Harītakī of course boosts the digestive fire. It has the quality to alleviate all the three dosa. It has all the rasa but for lavana, in the sadrasa. Madhuratikta-kasāya, rasa reduces the vitiated pitta. Likewise madhura-amla, reduces the vitiated vata and katutikta-kasāya reduces the vitiated kapha. Harītakī is of rūkṣaguṇa and uṣṇavīrya properties. Hence, aids in digestion and enhances the intelligence. Vipāka rasa is madhura. It has the qualities of rasayana, thereby improving the eye sight and longevity and is anulomaka. It is brmhana in nature. It also cures of the troubles due to santarpana. It has been proved to be very effective in śvāsa, kāsa, arśas, prameha, śopha, kustha, krmi, mahodara, svarasāda, grahanī, jvara, gulma, ānāha, vrana, chardi, hikkā, amlapitta, hrdroga, kāmala, śūla, pliharoga, yakrdroga, aśmari, mūtrakrchra, and so on. Again, this science advocates the use of seven types of haritaki for different ailments. It is said that vijaya variety is the best and can be used widely in all preparations. The commonly used variety is this, I guess, writes the author. But the common test to know the quality is to put har itak i in water and the one that is immersed/ the one that sinks is to be used. The exact weight of a haritaki is 6 kazañju.

Harītakī can be used as it is. One can chew it and it helps in digestion. It is good to enhance one's appetite. It can be used with food items (meals). It helps in excretions and improves one's enthuciasm. But decoction do not help in bowel movements, the physicians opines. But to take harītakī that is soaked overnight in buttermilk, early in the morning is good. But it is not advisable to chew harītakī in the following conditions; a person who is fatigued because of long walks, a weak person, rūkṣa and kṛśa individual, fatigued after laṅghana, diseased from pitta dosa, pregnant and after raktamoksana.

Harītakī is advised after food and it is very effective in the foresaid ailments. Powdered harītakī mixed with ghee is very good for people with vāta constitutions where vātadoṣa dominates; with sugar for pitta constitutions and with saindhava (rock salt) for kapha constitutions. Harītakī mixed with jaggery is advised for all. For rejuvenation the following is advised.

- Harītakī with rock salt in rainy season.
- Harītakī with sugar in autumn.
- Harītakī with śunthī (dried ginger/ Zingiber officinale Roscoe) in early winter.
- Harītakī with pippalī (*Piper longum* L.)in late winter.
- · Harītakī with jaggery in summer.

[Varṣam- Rainy, Śarat- Autumn, Hemantam- Early winter, Śiśiram- Late winter and Griṣmam-Summer.]

STATEMENT ABOUT OWNERSHIP AND OTHER PARTICULARS ABOUT NEWSPAPERS

(Aryavaidyan - Form II vide Rule 3)

1. Place of Publication Kottakkal

2. Periodicity of its Publication Quarterly: 4 times a year

3. Printer's name P.K. Warrier

Nationality Indian

Address Managing Trustee,

> Arya Vaidya Sala, Kottakkal- 676 503, Malappuram Dist., Kerala State.

(Printed at Geethanjali Offset Prints, Kozhikode)

4. Publisher's name P.K. Warrier

Nationality Indian

Address Managing Trustee,

Arya Vaidya Sala, Kottakkal- 676 503,

Malappuram Dist., Kerala State.

5. Editor's name Prof. (Dr.) K.G. Paulose

Nationality Indian

Address Publication Division,

Arya Vaidya Sala, Kottakkal- 676 503,

Malappuram Dist., Kerala State.

6. Name and address of individuals who own : Arya Vaidya Sala,

the Newspaper and Partners or Shareholders, Kottakkal.

holding more than 1% of the total Capital. (A Charitable Trust).

I, P.K. Warrier hereby declare that the particulars given above are true to the best of my knowledge and belief.

Sd/-

P.K.WARRIER

Kottakkal Publisher 15-2-2019

We invite papers on clinical research, clinical experiences, medicinal plants, drug development, drug processing and drug standardisation and also book reviews...

The language of the journal is English. All the manuscripts published are reviewed by eminent scholars around the globe.

The contents of the papers shall be the sole responsibility of the authors and publication shall not imply the concurrence of the Editors or Publishers. Manuscripts that are not accepted for publication will not be returned. Authors will be informed within three months of submission of manuscripts if they are recommended for publication in the journal. One copy of the journal will be sent to the author.

Manuscript presentation

Manuscript must be typed double spaced with margins of one inch (2.5cm) at the top, bottom and the sides and all pages numbered starting from the title page. 12 point Times New Roman font must be used and remain uniform throughout the text.

The manuscript should be divided into:

- i. Title page
- Second page with article title and Abstract (maximum 300 words for full papers and reviews or 200 words for short communications; without the use of references) followed by 3-5 key words
- iii. Introduction (state the objectives of the investigation with an adequate background)
- iv. Materials and methods (provide adequate details to enable others to reproduce; previously reported methods should be cited by a reference with a brief description of modifications)
- v. Results (clear and concise) and discussion separately or in combination is acceptable
- vi. Conclusion clearly and logically stated conclusion
- vii. Acknowledgements (should include credit to technical assistance, financial support and other appropriate recognition)
- viii. References
- ix. Tables
- x. Captions of figures
- xi. Figures


Research papers, review articles and short communications must be limited to 5000, 4000 and 2000 words in length respectively. The articles/papers may be sent to publications@aryavaidyasala.com For more details visit www.aryavaidyasala.com

Book Review


Authors/Publishers who wish their books to be reviewed in this journal are requested to send two copies of the same to the editor.


ARYAVAIDYAN


SUBSCRIPTION/RENEWAL SLIP				
wish to subscribe to the journal Aryavaidyan for 1 year 2 years 4 years				
I am sending DD/MO/ for Rs	(Rupeesonly).			
Name:				
Address:				
	Pin: ———			
Phone:	—— E-mail: —————			
Date:	Signature:			
%				
HOW TO SUBSCRIBE				
i Places fill in your name and address	g (in block latters)			
i Please fill in your name and addresii Tick the box to indicate the period				
iii Detach the slip and mail it at your				
	nafide certificate from the college for availing of the discount			
allowed.				
•	er by money order or by a demand draft (State Bank of India			
	e 338) / Vijaya Bank (Code 2017) / Punjab National Bank			
(Code 4297)) in favour of Arya Va	idya Sala, Kottakkal.			
For Online Payment				
SB A/c Name : Arya Vaidya Sala,	Kottakkal			
Account No. 57021886014 IFSC Code: SBIN 0070269				
Information to publications@aryav	vaidyasala.com will be appreciated after making the payment.			
SI	UBSCRIPTION RATES			
In India	Out of India (postal charges extra)			
Annual subscription : ₹ 400/				
Single copy : ₹ 120	1 т			
Concessional rate for bona	fide students of all systems of medicines in India			
Annual subscription : ₹ 320	/- Single copy : ₹ 90/-			



































































A Century Old Legacy of HEALING AND COMPASSION

AYURVEDA - THE AUTHENTIC WAY



Tel: 0483-2808000, 2742216, Fax:2742572, 2742210 E-mail: mail@aryavaidyasala.com / info@aryavaidyasala.com www.aryavaidyasala.com

BRANCHES: Adoor - 0473 4220440, Ahmedabad - 079 27489450, Aluva - 0484 2623549, Bangalore - 080 26572956, Chennai - 044 28251246, 47, Coimbatore - 0422 2491594, Ernakulam - 0484 2375674, Indore - 0731 2513335, Kannur - 0497 2761164, Kolkata - 033 24630661, Kottakkal - 0483 2743380, Kottayam - 0481 2304817/2562396, Kozhikode(Kallai Road) - 0495 2302666, Madurai - 0452 2623123, Mangalore - 0824 2443140, Mumbai, Matunga (E) - 022 24016879, 24015195, Mysore - 0821 2331062, New Delhi - 011 24621790, Palakkad(Vadakanthara) - 0491 2502404, Palakkad(Town) - 0491 2527084, Secunderabad - 040 27722226, Thiruvananthapuram - 0471 2463439, Thiruvananthapuram (Kazhakkoottam) - 0471 2413439, Thrissur - 0487 2380950, Tirur - 0494 2422231, Vijayawada - 0866 2578864/65 AYURVEDIC HOSPITAL & RESEARCH CENTRES: Kottakkal - 0483 2808000, Delhi - 011 22106500, Kochi - 0484 2554000